Synergistic fungicidal active substance combinations

ABSTRACT

Novel active compound combinations comprising a carboxamide of the general formula (I) (group 1) 
                         
in which
 
A, R 1 , R 2  and R 3  are as defined in the description,
 
and the active compound groups (2) to (23) listed in the description have very good fungicidal properties.

The present invention relates to novel active compound combinations comprising firstly known carboxamides and secondly further known fungicidally active compounds, which novel active compound combinations are highly suitable for controlling unwanted phytopathogenic fungi.

It is already known that certain carboxamides have fungicidal properties. Thus, for example, N-(3′,4′-dichloro-5-fluoro-1,1′-biphenyl-2-yl)-3-(difluoromethyl)-1-methyl-1H-pyrazole-4-carboxamide is known from DE-A 102 15 292, 3-(trifluoromethyl)-N-{3′-fluoro-4′-[(E)-(methoxyimino)methyl]-1,1′-biphenyl-2-yl}-1-methyl-1H-pyrazole-4-carboxamide is known from WO 02/08197 and N-(3′,4′-dichloro-1,1′-biphenyl-2-yl)-5-fluoro-1,3-dimethyl-1H-pyrazole-4-carboxamide is known WO 00/14701. The activity of these compounds is good; however, at low application rates it is sometimes unsatisfactory. Furthermore, it is already known that numerous triazole derivatives, aniline derivatives, dicarboximides and other heterocycles can be used for controlling fungi (cf. EP-A 0 040 345, DE-A 22 01 063, DE-A 23 24 010, Pesticide Manual, 9th Edition (1991), pages 249 and 827, EP-A 0 382 375 and EP-A 0 515 901). However, the action of these compounds is likewise not always sufficient at low application rates. Furthermore, it is already known that 1-(3,5-dimethylisoxazole-4-sulphonyl)-2-chloro-6,6-difluoro-[1,3]-dioxolo-[4,5f]-benzimidazole has fungicidal properties (cf. WO 97/06171). Finally, it is also known that substituted halopyrimidines have fungicidal properties (cf. DE-A1-196 46 407, EP-B 0 712 396).

The present invention now provides novel active compound combinations having very good fungicidal properties and comprising a carboxamide of the general formula (I) (group 1)

in which

-   R¹ represents hydrogen or fluorine, -   R² represents halogen, C₁-C₃-alkyl, C₁-C₃-haloalkyl having 1 to 7     fluorine, chlorine and/or bromine atoms, C₁-C₃-alkoxy,     C₁-C₃-haloalkoxy having 1 to 7 fluorine, chlorine and/or bromine     atoms or represents —C(R⁴)═N—OR⁵, -   R³ represents hydrogen, halogen, C₁-C₃-alkyl or C₁-C₃-haloalkyl     having 1 to 7 fluorine, chlorine and/or bromine atoms, -   R⁴ represents hydrogen or methyl, -   R⁵ represents C₁-C₅-alkyl, C₁-C₅-alkenyl or C₁-C₅-alkynyl, -   A represents one of the radicals A1 to A7 below:

-   R⁶ represents C₁-C₃-alkyl, -   R⁷ represents hydrogen, halogen, C₁-C₃-alkyl or C₁-C₃-haloalkyl     having 1 to 7 fluorine, chlorine and/or bromine atoms, -   R⁸ represents hydrogen, halogen or C₁-C₃-alkyl, -   R⁹ represents hydrogen, halogen, C₁-C₃-alkyl, amino, mono- or     di(C₁-C₃-alkyl)amino, -   R¹⁰ represents hydrogen, halogen, C₁-C₃-alkyl or C₁-C₃-haloalkyl     having 1 to 7 fluorine, chlorine and/or bromine atoms, -   R¹¹ represents halogen, C₁-C₃-alkyl or C₁-C₃-haloalkyl having 1 to 7     fluorine, chlorine and/or bromine atoms, -   R¹² represents halogen, C₁-C₃-alkyl or C₁-C₃-haloalkyl having 1 to 7     fluorine, chlorine and/or bromine atoms, -   R¹³ represents hydrogen, halogen, C₁-C₃-alkyl or C₁-C₃-haloalkyl     having 1 to 7 fluorine, chlorine and/or bromine atoms, -   and at least one active compound selected from groups (2) to (23)     below:     Group (2) Strobilurins of the General Formula (II)

in which

-   A¹ represents one of the groups

-   A² represents NH or O, -   A³ represents N or CH, -   L represents one of the groups

-   -   where the bond marked with an asterisk (*) is attached to the         phenyl ring,

-   R¹⁴ represents phenyl, phenoxy or pyridinyl, each of which is     optionally mono- or disubstituted by identical or different     substituents from the group consisting of chlorine, cyano, methyl     and trifluoromethyl, or represents 1-(4-chlorophenyl)-pyrazol-3-yl     or represents 1,2-propane-dione-bis(O-methyloxime)-1-yl,

-   R¹⁵ represents hydrogen or fluorine;     Group (3) Triazoles of the General Formula (III)

in which

-   Q represents hydrogen or SH, -   m represents 0 or 1, -   R¹⁶ represents hydrogen, fluorine, chlorine, phenyl or     4-chlorophenoxy, -   R¹⁷ represents hydrogen or chlorine, -   A⁴ represents a direct bond, —CH₂—, —(CH₂)₂— or —O—, -   A⁴ furthermore represents *—CH₂—CHR²⁰— or *—CH═CR²⁰— where the bond     marked with * is attached to the phenyl ring, and     -   R¹⁸ and R²⁰ furthermore together represent         —CH₂—CH₂—CH[CH(CH₃)₂]— or —CH₂—CH₂—C(CH₃)₂—, -   A⁵ represents C or Si (silicon), -   A⁴ further represents —N(R²⁰)— and A⁵ furthermore together with R¹⁸     and R¹⁹ represents the group C═N—R²¹, in which case R²⁰ and R²¹     together represent the group

where the bond marked with * is attached to R²⁰,

-   R¹⁸ represents hydrogen, hydroxyl or cyano, -   R¹⁹ represents 1-cyclopropylethyl, 1-chlorocyclopropyl, C₁-C₄-alkyl,     C₁-C₆-hydroxyalkyl, C₁-C₄-alkylcarbonyl,     C₁-C₂-haloalkoxy-C₁-C₂-alkyl, trimethylsilyl-C₁-C₂-alkyl,     monofluorophenyl or phenyl, -   R¹⁸ and R¹⁹ furthermore together represent —O—CH₂—CH(R²¹)—O—,     —O—CH₂—CH(R²¹)—CH₂—, or —O—CH(2-chlorophenyl)-, -   R²¹ represents hydrogen, C₁-C₄-alkyl or bromine;     Group (4) Sulphenamides of the General Formula (IV)

in which R²² represents hydrogen or methyl; Group (5) Valinamides Selected from

-   (5-1) iprovalicarb -   (5-2)     N-[2-(4-{[3-(4-chlorophenyl)-2-propynyl]oxy}-3-methoxyphenyl)ethyl]-N²-(methylsulphonyl)-D-valinamide -   (5-3) benthiavalicarb     Group (6) Carboxamides of the General Formula

in which

-   X represents 2-chloro-3-pyridinyl, represents 1-methylpyrazol-4-yl     which is substituted in the 3-position by methyl or trifluoromethyl     and in the 5-position by hydrogen or chlorine, represents     4-ethyl-2-ethylamino-1,3-thiazol-5-yl, represents     1-methylcyclohexyl, represents     2,2-dichloro-1-ethyl-3-methylcyclopropyl, represents     2-fluoro-2-propyl or represents phenyl which is mono- to     trisubstituted by identical or different substituents from the group     consisting of chlorine and methyl, -   X furthermore represents 3,4-dichloroisothiazol-5-yl,     5,6-dihydro-2-methyl-1,4-oxathiin-3-yl,     4-methyl-1,2,3-thiadiazol-5-yl,     4,5-dimethyl-2-trimethylsilylthiophen-3-yl, 1-methylpyrrol-3-yl     which is substituted in the 4-position by methyl or trifluoromethyl     and in the 5-position by hydrogen or chlorine, -   Y represents a direct bond, C₁-C₆-alkanediyl (alkylene) which is     optionally substituted by chlorine, cyano or oxo or represents     thiophenediyl, -   Y furthermore represents C₂-C₆-alkenediyl (alkenylene), -   Z represents hydrogen or the group

-   Z furthermore represents C₁-C₆-alkyl, -   A⁶ represents CH or N, -   R²³ represents hydrogen, chlorine, phenyl which is optionally mono-     or disubstituted by identical or different substituents from the     group consisting of chlorine and di(C₁-C₃-alkyl)aminocarbonyl, -   R²³ furthermore represents cyano or C₁-C₆-alkyl, -   R²⁴ represents hydrogen or chlorine, -   R²⁵ represents hydrogen, chlorine, hydroxyl, methyl or     trifluoromethyl, -   R²⁵ furthermore represents di(C₁-C₃-alkyl)aminocarbonyl, -   R²³ and R²⁴ furthermore together represent *—CH(CH₃)—CH₂—C(CH₃)₂— or     *—CH(CH₃)—O—C(CH₃)₂— where the bond marked with * is attached to     R²³;     Group (7) Dithiocarbamates Selected from -   (7-1) mancozeb -   (7-2) maneb -   (7-3) metiram -   (7-4) propineb -   (7-5) thiram -   (7-6) zineb -   (7-7) ziram     Group (8) Acylalanines of the General Formula (VI)

in which

-   * marks a carbon atom in the R or the S configuration, preferably in     the S configuration, -   R²⁶ represents benzyl, furyl or methoxymethyl;     Group (9): Anilinopyrimidines of the General Formula (VII)

in which

-   R²⁷ represents methyl, cyclopropyl or 1-propynyl;     Group (10): Benzimidazoles of the General Formula (VIII)

in which

-   R²⁸ and R²⁹ each represent hydrogen or together represent —O—CF₂—O—, -   R³⁰ represents hydrogen, C₁-C₄-alkylaminocarbonyl or represents     3,5-dimethylisoxazol-4-ylsulphonyl, -   R³¹ represents chlorine, methoxycarbonylamino, chlorophenyl, furyl     or thiazolyl;     Group (11): Carbamates of the General Formula (IX)

in which

-   R³² represents n- or isopropyl, -   R³³ represents di(C₁-C₂-alkyl)amino-C₂-C₄-alkyl or diethoxyphenyl, -   salts of these compounds also being included;     Group (12): Dicarboximides Selected from -   (12-1) captafol -   (12-2) captan -   (12-3) folpet -   (12-4) iprodione -   (12-5) procymidone -   (12-6) vinclozolin     Group (13): Guanidines Selected from -   (13-1) dodine -   (13-2) guazatine -   (13-3) iminoctadine triacetate -   (13-4) iminoctadine tris(albesilate)     Group (14): Imidazoles Selected from -   (14-1) cyazofamid -   (14-2) prochloraz -   (14-3) triazoxide -   (14-4) pefurazoate     Group (15): Morpholines of the General Formula (X)

in which

-   R³⁴ and R³⁵ independently of one another represent hydrogen or     methyl, -   R³⁶ represents C₁-C₁₄-alkyl (preferably C₁₂-C₁₄-alkyl),     C₅-C₁₂-cycloalkyl (preferably C₁₀-C₁₂-cycloalkyl),     phenyl-C₁-C₄-alkyl, which may be substituted in the phenyl moiety by     halogen or -   C₁-C₄-alkyl or represents acrylyl which is substituted by     chlorophenyl and dimethoxyphenyl;     Group (16): Pyrroles of the General Formula (XI)

in which

-   R³⁷ represents chlorine or cyano, -   R³⁸ represents chlorine or nitro, -   R³⁹ represents chlorine, -   R³⁸ and R³⁹ furthermore together represent —O—CF₂—O—;     Group (17): Phosphonates Selected from -   (17-1) fosetyl-Al -   (17-2) phosphonic acid;     Group (18): Phenylethanamides of the General Formula (XII)

in which

-   R⁴⁰ represents unsubstituted or fluorine-, chlorine-, bromine-,     methyl- or ethyl-substituted phenyl, 2-naphthyl,     1,2,3,4-tetrahydronaphthyl or indanyl;     Group (19): Fungicides Selected from -   (19-1) acibenzolar-S-methyl -   (19-2) chlorothalonil -   (19-3) cymoxanil -   (19-4) edifenphos -   (19-5) famoxadone -   (19-6) fluazinam -   (19-7) copper oxychloride -   (19-8) copper hydroxide -   (19-9) oxadixyl -   (19-10) spiroxamine -   (19-11) dithianon -   (19-12) metrafenone -   (19-13) fenamidone -   (19-14) 2,3-dibutyl-6-chlorothieno[2,3-d]pyrimidin-4(3H)-one -   (19-15) probenazole -   (19-16) isoprothiolane -   (19-17) kasugamycin -   (19-18) phthalide -   (19-19) ferimzone -   (19-20) tricyclazole -   (19-21)     N-({4-[(cyclopropylamino)carbonyl]phenyl}sulphonyl)-2-methoxybenzamide -   (19-22)     2-(4-chlorophenyl)-N-{2-[3-methoxy-4-(prop-2-yn-1-yloxy)phenyl]ethyl}-2-(prop-2-yn-1-yloxy)acetamide     Group (20): (Thio)Urea Derivatives Selected from -   (20-1) pencycuron -   (20-2) thiophanate-methyl -   (20-3) thiophanate-ethyl     Group (21): Amides of the General Formula (XIII)

in which

-   A⁷ represents a direct bond or —O—, -   A⁸ represents —C(═O)NH— or —NHC(═O)—, -   R⁴¹ represents hydrogen or C₁-C₄-alkyl, -   R⁴² represents C₁-C₆-alkyl;     Group (22): Triazolopyrimidines of the General Formula (XIV)

in which

-   R⁴³ represents C₁-C₆-alkyl or C₂-C₆-alkenyl, -   R⁴⁴ represents C₁-C₆-alkyl, -   R⁴³ and R⁴⁴ furthermore together represent C₄-C₅-alkanediyl     (alkylene) which is mono- or disubstituted by C₁-C₆-alkyl, -   R⁴⁵ represents bromine or chlorine, -   R⁴⁶ and R⁵⁰ independently of one another represent hydrogen,     fluorine, chlorine or methyl, -   R⁴⁷ and R⁴⁹ independently of one another represent hydrogen or     fluorine, -   R⁴⁸ represents hydrogen, fluorine or methyl,     Group (23): Iodochromones of the General Formula (XV)

in which

-   R⁵¹ represents C₁-C₆-alkyl, -   R⁵² represents C₁-C₆-alkyl, C₂-C₆-alkenyl or C₂-C₆-alkynyl.

Surprisingly, the fungicidal action of the active compound combinations according to the invention is considerably better than the sum of the activities of the individual active compounds. Thus, an unforeseeable true synergistic effect is present, and not just an addition of actions.

The formula (I) provides a general definition of the compounds of group (1).

-   Preference is given to carboxamides of the formula (I) in which -   R¹ represents hydrogen or fluorine, -   R² represents fluorine, chlorine, bromine, iodine, methyl,     trifluoromethyl, trifluoromethoxy or represents —C(R⁴)═N—OR⁵, -   R³ represents hydrogen, fluorine, chlorine, bromine, methyl or     trifluoromethyl, -   R⁴ represents hydrogen or methyl, -   R⁵ represents C₁-C₅-alkyl, -   A represents one of the radicals A1 to A7 below:

-   R⁶ represents methyl, -   R⁷ represents iodine, methyl, difluoromethyl or trifluoromethyl, -   R⁸ represents hydrogen, fluorine, chlorine or methyl, -   R⁹ represents hydrogen, chlorine, methyl, amino or dimethylamino, -   R¹⁰ represents methyl, difluoromethyl or trifluoromethyl, -   R¹¹ represents chlorine, bromine, iodine, methyl, difluoromethyl or     trifluoromethyl, -   R¹² represents bromine or methyl, -   R¹³ represents methyl or trifluoromethyl.

Particular preference is given to carboxamides of the formula (I) in which

-   R¹ represents hydrogen or fluorine, -   R² represents fluorine, chlorine, bromine, trifluoromethyl or     represents —CH═N—OCH₃, -   R³ represents hydrogen, fluorine or chlorine, -   A represents one of the radicals A1 to A5 below:

-   R⁶ represents methyl, -   R⁷ represents methyl, difluoromethyl or trifluoromethyl, -   R⁸ represents hydrogen or fluorine, -   R⁹ represents methyl, -   R¹⁰ represents methyl, difluoromethyl or trifluoromethyl, -   R¹¹ represents iodine, difluoromethyl or trifluoromethyl, -   R¹² represents methyl, -   R¹³ represents methyl or trifluoromethyl.

Very particular preference is given to carboxamides of the formula (I) in which

-   R¹ represents hydrogen or fluorine, -   R² represents fluorine, chlorine, bromine, trifluoromethyl or     represents —CH═N—OCH₃, -   R³ represents hydrogen, fluorine or chlorine, -   A represents one of the radicals A1 or A2 below:

-   R⁶ represents methyl, -   R⁷ represents methyl, difluoromethyl or trifluoromethyl, -   R⁸ represents hydrogen or fluorine, -   R⁹ represents methyl, -   R¹⁰ represents methyl, difluoromethyl or trifluoromethyl.

Very particular preference is given to using, in mixtures, compounds of the formula (Ia)

in which R¹, R², R³, R⁶, R⁷ and R⁸ are as defined above.

Very particular preference is given to using, in mixtures, compounds of the formula (Ib)

in which R¹, R², R³, R⁹ and R¹⁰ are as defined above.

The formula (I) embraces in particular the following preferred mixing partners of group (1):

-   (1-1)     N-(3′,4′-dichloro-5-fluoro-1,1′-biphenyl-2-yl)-3-(difluoromethyl)-1-methyl-1H-pyrazole-4-carboxamide     (known from WO 03/070705) -   (1-2)     3-(difluoromethyl)-N-{3′-fluoro-4′-[(E)-(methoxyimino)methyl]-1,1′-biphenyl-2-yl}-1-methyl-1H-pyrazole-4-carboxamide     (known from WO 02/08197) -   (1-3)     3-(trifluoromethyl)-N-{3′-fluoro-4′-[(E)-(methoxyimino)methyl]-1,1′-biphenyl-2-yl}-1-methyl-1H-pyrazole-4-carboxamide     (known from WO 02/08197) -   (1-4)     N-(3′,4′-dichloro-1,1′-biphenyl-2-yl)-5-fluoro-1,3-dimethyl-1H-pyrazole-4-carboxamide     (known from WO 00/14701) -   (1-5)     N-(4′-chloro-3′-fluoro-1,1′-biphenyl-2-yl)-2-methyl-4-(trifluoromethyl)-1,3-thiazole-5-carboxamide     (known from WO 03/066609) -   (1-6)     N-(4′-chloro-1,1′-biphenyl-2-yl)-4-(difluoromethyl)-2-methyl-1,3-thiazole-5-carboxamide     (known from WO 03/066610) -   (1-7)     N-(4′-bromo-1,1′-biphenyl-2-yl)-4-(difluoromethyl)-2-methyl-1,3-thiazole-5-carboxamide     (known from WO 03/066610) -   (1-8)     4-(difluoromethyl)-2-methyl-N-[4′-(trifluoromethyl)-1,1′-biphenyl-2-yl]-1,3-thiazole-5-carboxamide     (known from WO 03/066610) -   (1-9)     N-(4′-chloro-3′-fluoro-1,1′-biphenyl-2-yl)-4-(difluoromethyl)-2-methyl-1,3-thiazole-5-carboxamide     (known from WO 03/066610)

Emphasis is given to active compound combinations according to the invention which, in addition to carboxamide (1-1) N-(3′,4′-dichloro-5-fluoro-1,1′-biphenyl-2-yl)-3-(difluoromethyl)-1-methyl-1H-pyrazole-4-carboxamide (group 1) comprise one or more, preferably one, mixing partner of groups (2) to (23).

Emphasis is given to active compound combinations according to the invention which, in addition to carboxamide (1-7) N-(4′-bromo-1,1′-biphenyl-2-yl)-4-(difluoromethyl)-2-methyl-1,3-thiazole-5-carboxamide (group 1) comprise one or more, preferably one, mixing partner of groups (2) to (23).

Emphasis is given to active compound combinations according to the invention which, in addition to carboxamide (1-8) 4-(difluoromethyl)-2-methyl-N-[4′-(trifluoromethyl)-1,1′-biphenyl-2-yl]-1,3-thiazole-5-carboxamide (group 1) comprise one or more, preferably one, mixing partner of groups (2) to (23).

Emphasis is given to active compound combinations according to the invention which, in addition to carboxamide (1-9) N-(4′-chloro-3′-fluoro-1,1′-biphenyl-2-yl)-4-(difluoromethyl)-2-methyl-1,3-thiazole-5-carboxamide (group 1) comprise one or more, preferably one, mixing partner of groups (2) to (23).

The formula (II) embraces the following preferred mixing partners of group (2):

-   (2-1) azoxystrobin (known from EP-A 0 382 375) of the formula

-   (2-2) fluoxastrobin (known from DE-A 196 02 095) of the formula

-   (2-3)     (2E)-2-(2-{[6-(3-chloro-2-methylphenoxy)-5-fluoro-4-pyrimidinyl]oxy}phenyl)-2-(methoxy-imino)-N-methylethanamide     (known from DE-A 196 46 407, EP-B 0 712 396) of the formula

-   (2-4) trifloxystrobin (known from EP-A 0 460 575) of the formula

-   (2-5)     (2E)-2-(methoxyimino)-N-methyl-2-(2-{[({(1E)-1-[3-(trifluoromethyl)phenyl]ethylidene}-amino)oxy]methyl}phenyl)ethanamide     (known from EP-A 0 569 384) of the formula

-   (2-6)     (2E)-2-(methoxyimino)-N-methyl-2-{2-[(E)-({1-[3-(trifluoromethyl)phenyl)ethoxy}imino)-methyl]phenyl}ethanamide     (known from EP-A 0 596 254) of the formula

-   (2-7) orysastrobin (known from DE-A 195 39 324) of the formula

-   (2-8)     5-methoxy-2-methyl-4-(2-{[({(1E)-1-[3-(trifluoromethyl)phenyl]ethylidene}amino)oxy]-methyl}phenyl)-2,4-dihydro-3H-1,2,4-triazol-3-one     (known from WO 98/23155) of the formula

-   (2-9) kresoxim-methyl (known from EP-A 0 253 213) of the formula

-   (2-10) dimoxystrobin (known from EP-A 0 398 692) of the formula

-   (2-11) picoxystrobin (known from EP-A 0 278 595) of the formula

-   (2-12) pyraclostrobin (known from DE-A 44 23 612) of the formula

-   (2-13) metominostrobin (known from EP-A 0 398 692) of the formula

The formula (III) embraces the following preferred mixing partners of group (3):

-   (3-1) azaconazole (known from DE-A 25 51 560) of the formula

-   (3-2) etaconazole (known from DE-A 25 51 560) of the formula

-   (3-3) propiconazole (known from DE-A 25 51 560) of the formula

-   (3-4) difenoconazole (known from EP-A 0 112 284) of the formula

-   (3-5) bromuconazole (known from EP-A 0 258 161) of the formula

-   (3-6) cyproconazole (known from DE-A 34 06 993) of the formula

-   (3-7) hexaconazole (known from DE-A 30 42 303) of the formula

-   (3-8) penconazole (known from DE-A 27 35 872) of the formula

-   (3-9) myclobutanil (known from EP-A 0 145 294) of the formula

-   (3-10) tetraconazole (known from EP-A 0 234 242) of the formula

-   (3-11) flutriafol (known from EP-A 0 015 756) of the formula

-   (3-12) epoxiconazole (known from EP-A 0 196 038) of the formula

-   (3-13) flusilazole (known from EP-A 0 068 813) of the formula

-   (3-14) simeconazole (known from EP-A 0 537 957) of the formula

-   (3-15) prothioconazole (known from WO 96/16048) of the formula

-   (3-16) fenbuconazole (known from DE-A 37 21 786) of the formula

-   (3-17) tebuconazole (known from EP-A 0 040 345) of the formula

-   (3-18) ipconazole (known from EP-A 0 329 397) of the formula

-   (3-19) metconazole (known from EP-A 0 329 397) of the formula

-   (3-20) triticonazole (known from EP-A 0 378 953) of the formula

-   (3-21) bitertanol (known from DE-A 23 24 010) of the formula

-   (3-22) triadimenol (known from DE-A 23 24 010) of the formula

-   (3-23) triadimefon (known from DE-A 22 01 063) of the formula

-   (3-24) fluquinconazole (known from EP-A 0 183 458) of the formula

-   (3-25) quinconazole (known from EP-A 0 183 458) of the formula

The formula (IV) embraces the following preferred mixing partners of group (4):

-   (4-1) dichlofluanid (known from DE-A 11 93 498) of the formula

-   (4-2) tolylfluanid (known from DE-A 11 93 498) of the formula

Preferred mixing partners of group (5) are

-   (5-1) iprovalicarb (known from DE-A 40 26 966) of the formula

-   (5-3) benthiavalicarb (known from WO 96/04252) of the formula

The formula (V) embraces the following preferred mixing partners of group (6):

-   (6-1) 2-chloro-N-(1,1,3-trimethylindan-4-yl)nicotinamide (known from     EP-A 0 256 503) of the formula

-   (6-2) boscalid (known from DE-A 195 31 813) of the formula

-   (6-3) furametpyr (known from EP-A 0 315 502) of the formula

-   (6-4)     N-(3-p-tolylthiophen-2-yl)-1-methyl-3-trifluoromethyl-1H-pyrazole-4-carboxamide     (known from EP-A 0 737 682) of the formula

-   (6-5) ethaboxam (known from EP-A 0 639 574) of the formula

-   (6-6) fenhexamid (known from EP-A 0 339 418) of the formula

-   (6-7) carpropamid (known from EP-A 0 341 475) of the formula

-   (6-8)     2-chloro-4-(2-fluoro-2-methylpropionylamino)-N,N-dimethylbenzamide     (known from EP-A 0 600 629) of the formula

-   (6-9) picobenzamid (known from WO 99/42447) of the formula

-   (6-10) zoxamide (known from EP-A 0 604 019) of the formula

-   (6-11) 3,4-dichloro-N-(2-cyanophenyl)isothiazole-5-carboxamide     (known from WO 99/24413) of the formula

-   (6-12) carboxin (known from U.S. Pat. No. 3,249,499) of the formula

-   (6-13) tiadinil (known from U.S. Pat. No. 6,616,054) of the formula

-   (6-14) penthiopyrad (known from EP-A 0 737 682) of the formula

-   (6-15) silthiofam (known from WO 96/18631) of the formula

-   (6-16)     N-[2-(1,3-dimethylbutyl)phenyl]-1-methyl-4-(trifluoromethyl)-1H-pyrrole-3-carboxamide     (known from WO 02/38542) of the formula

Preferred mixing partners of group (7) are

-   (7-1) mancozeb (known from DE-A 12 34 704) having the IUPAC name     manganese ethylenebis(dithiocarbamate) (polymeric) complex with zinc     salt -   (7-2) maneb (known from U.S. Pat. No. 2,504,404) of the formula

-   (7-3) metiram (known from DE-A 10 76 434) having the IUPAC name zinc     ammoniate ethylenebis(dithiocarbamate)-poly(ethylenethiuram     disulphide) -   (7-4) propineb (known from GB 935 981) of the formula

-   (7-5) thiram (known from U.S. Pat. No. 1,972,961) of the formula

-   (7-6) zineb (known from DE-A 10 81 446) of the formula

-   (7-7) ziram (known from U.S. Pat. No. 2,588,428) of the formula

The formula (VI) embraces the following preferred mixing partners of group (8):

-   (8-1) benalaxyl (known from DE-A 29 03 612) of the formula

-   (8-2) furalaxyl (known from DE-A 25 13 732) of the formula

-   (8-3) metalaxyl (known from DE-A 25 15 091) of the formula

-   (8-4) metalaxyl-M (known from WO 96/01559) of the formula

-   (8-5) benalaxyl-M of the formula

The formula (VII) embraces the following preferred mixing partners of group (9):

-   (9-1) cyprodinil (known from EP-A 0 310 550) of the formula

-   (9-2) mepanipyrim (known from EP-A 0 270 111) of the formula

-   (9-3) pyrimethanil (known from DD 151 404) of the formula

The formula (VIII) embraces the following preferred mixing partners of group (10):

-   (10-1)     6-chloro-5-[(3,5-dimethylisoxazol-4-yl)sulphonyl]-2,2-difluoro-5H-[1,3]dioxolo[4,5-f]-benzimidazole     (known from WO 97/06171) of the formula

-   (10-2) benomyl (known from U.S. Pat. No. 3,631,176) of the formula

-   (10-3) carbendazim (known from U.S. Pat. No. 3,010,968) of the     formula

-   (10-4) chlorfenazole of the formula

-   (10-5 fuberidazole (known from DE-A 12 09 799) of the formula

-   (10-6) thiabendazole (known from U.S. Pat. No. 3,206,468) of the     formula

The formula (IX) embraces the following preferred mixing partners of group (11):

-   (11-1) diethofencarb (known from EP-A 0 078 663) of the formula

-   (11-2) propamocarb (known from U.S. Pat. No. 3,513,241) of the     formula

-   (11-3) propamocarb-hydrochloride (known from U.S. Pat. No.     3,513,241) of the formula

-   (11-4) propamocarb-fosetyl of the formula

Preferred mixing partners of group (12) are

-   (12-1) captafol (known from U.S. Pat. No. 3,178,447) of the formula

-   (12-2) captan (known from U.S. Pat. No. 2,553,770) of the formula

-   (12-3) folpet (known from U.S. Pat. No. 2,553,770) of the formula

-   (12-4) iprodione (known from DE-A 21 49 923) of the formula

-   (12-5) procymidone (known from DE-A 20 12 656) of the formula

-   (12-6) vinclozolin (known from DE-A 22 07 576) of the formula

Preferred mixing partners of group (13) are

-   (13-1) dodine (known from GB 11 03 989) of the formula

-   (13-2) guazatine (known from GB 11 14 155) -   (13-3) iminoctadine triacetate (known from EP-A 0 155 509) of the     formula

Preferred mixing partners of the group (14) are

-   (14-1) cyazofamid (known from EP-A 0 298 196) of the formula

-   (14-2) prochloraz (known from DE-A 24 29 523) of the formula

-   (14-3) triazoxide (known from DE-A 28 02 488) of the formula

-   (14-4) pefurazoate (known from EP-A 0 248 086) of the formula

The formula (X) embraces the following preferred mixing partners of group (15):

-   (15-1) aldimorph (known from DD 140 041) of the formula

-   (15-2) tridemorph (known from GB 988 630) of the formula

-   (15-3) dodemorph (known from DE-A 25 432 79) of the formula

-   (15-4) fenpropimorph (known from DE-A 26 56 747) of the formula

-   (15-5) dimethomorph (known from EP-A 0 219 756) of the formula

The formula (XI) embraces the following preferred mixing partners of group (16):

-   (16-1) fenpiclonil (known from EP-A 0 236 272) of the formula

-   (16-2) fludioxonil (known from EP-A 0 206 999) of the formula

-   (16-3) pyrrolnitrin (known from JP 65-25876) of the formula

Preferred mixing partners of group (17) are

-   (17-1) fosetyl-Al (known from DE-A 24 56 627) of the formula

-   (17-2) phosphonic acid (known chemical) of the formula

The formula (XII) embraces the following preferred mixing partners of group (18) which are known from WO 96/23793 and can in each case be present as E or Z isomers. Accordingly, compounds of the formula (XII) can be present as a mixture of different isomers or else in the form of a single isomer. Preference is given to compounds of the formula (XII) in the form of their E isomers:

-   (18-1)     2-(2,3-dihydro-1H-inden-5-yl)-N-[2-(3,4-dimethoxyphenyl)ethyl]-2-(methoxy-imino)acetamide     of the formula

-   (18-2)     N-[2-(3,4-dimethoxyphenyl)ethyl]-2-(methoxyimino)-2-(5,6,7,8-tetrahydronaphthalen-2-yl)acetamide     of the formula

-   (18-3)     2-(4-chlorophenyl)-N-[2-(3,4-dimethoxyphenyl)ethyl]-2-(methoxyimino)acetamide     of the formula

-   (18-4)     2-(4-bromophenyl)-N-[2-(3,4-dimethoxyphenyl)ethyl]-2-(methoxyimino)acetamide     of the formula

-   (18-5)     2-(4-methylphenyl)-N-[2-(3,4-dimethoxyphenyl)ethyl]-2-(methoxyimino)acetamide     of the formula

-   (18-6)     2-(4-ethylphenyl)-N-[2-(3,4-dimethoxyphenyl)ethyl]-2-(methoxyimino)acetamide     of the formula

Preferred mixing partners of group (19) are

-   (19-1) acibenzolar-S-methyl (known from EP-A 0 313 512) of the     formula

-   (19-2) chlorothalonil (known from U.S. Pat. No. 3,290,353) of the     formula

-   (19-3) cymoxanil (known from DE-A 23 12 956) of the formula

-   (19-4) edifenphos (known from DE-A 14 93 736) of the formula

-   (19-5) famoxadone (known from EP-A 0 393 911) of the formula

-   (19-6) fluazinam (known from EP-A 0 031 257) of the formula

-   (19-7) copper oxychloride -   (19-9) oxadixyl (known from DE-A 30 30 026) of the formula

-   (19-10) spiroxamine (known from DE-A 37 35 555) of the formula

-   (19-11) dithianon (known from JP-A 44-29464) of the formula

-   (19-12) metrafenone (known from EP-A 0 897 904) of the formula

-   (19-13) fenamidone (known from EP-A 0 629 616) of the formula

-   (19-14) 2,3-dibutyl-6-chlorothieno[2,3-d]pyrimidin-4(3H)one (known     from WO 99/14202) of the formula

-   (19-15) probenazole (known from U.S. Pat. No. 3,629,428) of the     formula

-   (19-16) isoprothiolane (known from U.S. Pat. No. 3,856,814) of the     formula

-   (19-17) kasugamycin (known from GB 1 094 567) of the formula

-   (19-18) phthalide (known from JP-A 57-55844) of the formula

-   (19-19) ferimzone (known from EP-A 0 019 450) of the formula

-   (19-20) tricyclazole (known from DE-A 22 50 077) of the formula

-   (19-21)     N-({4-[(cyclopropylamino)carbonyl]phenyl}sulphonyl)-2-methoxybenzamide     of the formula

-   (19-22)     2-(4-chlorophenyl)-N-{2-[3-methoxy-4-(prop-2-yn-1-yloxy)phenyl]ethyl}-2-(prop-2-yn-1-yloxy)acetamide     (known from WO 01/87822) of the formula

Preferred mixing partners of group (20) are

-   (20-1) pencycuron (known from DE-A 27 32 257) of the formula

-   (20-2) thiophanate-methyl (known from DE-A 18 06 123) of the formula

-   (20-3) thiophanate-ethyl (known from DE-A 18 06 123) of the formula

Preferred mixing partners of group (21) are

-   (21-1) fenoxanil (known from EP-A 0 262 393) of the formula

-   (21-2) diclocymet (known from JP-A 7-206608) of the formula

Preferred mixing partners of group (22) are

-   (22-1)     5-chloro-N-[(1S)-2,2,2-trifluoro-1-methylethyl]-6-(2,4,6-trifluorophenyl)[1,2,4]triazolo-[1,5-a]pyrimidine-7-amine     (known from U.S. Pat. No. 5,986,135) of the formula

-   (22-2)     5-chloro-N-[(1R)-1,2-dimethylpropyl]-6-(2,4,6-trifluorophenyl)[1,2,4]triazolo[1,5-a]-pyrimidine-7-amine     (known from WO 02/38565) of the formula

-   (22-3)     5-chloro-6-(2-chloro-6-fluorophenyl)-7-(4-methylpiperidin-1-yl)[1,2,4]triazolo[1,5-a]-pyrimidine     (known from U.S. Pat. No. 5,593,996) of the formula

-   (22-4)     5-chloro-6-(2,4,6-trifluorophenyl)-7-(4-methylpiperidin-1-yl)[1,2,4]triazolo[1,5-a]pyrimidine     (known from DE-A 101 24 208) of the formula

Preferred mixing partners of group (23) are

-   (23-1) 2-butoxy-6-iodo-3-propylbenzopyran-4-one (known from WO     03/014103) of the formula

-   (23-2) 2-ethoxy-6-iodo-3-propylbenzopyran-4-one (known from WO     03/014103) of the formula

-   (23-3) 6-iodo-2-propoxy-3-propylbenzopyran-4-one (known from WO     03/014103) of the formula

-   (23-4) 2-but-2-ynyloxy-6-iodo-3-propylbenzopyran-4-one (known from     WO 03/014103) of the formula

-   (23-5) 6-iodo-2-(1-methylbutoxy)-3-propylbenzopyran-4-one (known     from WO 03/014103) of the formula

-   (23-6) 2-but-3-enyloxy-6-iodobenzopyran-4-one (known from WO     03/014103) of the formula

-   (23-7) 3-butyl-6-iodo-2-isopropoxybenzopyran-4-one (known from WO     03/014103) of the formula

Compound (6-7), carpropamid, has three asymmetrically substituted carbon atoms. Accordingly, compound (6-7) can be present as a mixture of different isomers or else in the form of a single component. Particular preference is given to the compounds

-   (1S,3R)-2,2-dichloro-N-[(1R)-1-(4-chlorophenyl)ethyl]-1-ethyl-3-methylcyclopropanecarboxamide     of the formula

-   (1R,3S)-2,2-dichloro-N-[(1R)-1-(4-chlorophenyl)ethyl]-1-ethyl-3-methylcyclopropanecarboxamide     of the formula

Particularly preferred mixing partners are the following active compounds:

-   (2-1) azoxystrobin -   (2-2) fluoxastrobin -   (2-3)     (2E)-2-(2-{[6-(3-chloro-2-methylphenoxy)-5-fluoro-4-pyrimidinyl]oxy}phenyl)-2-(methoxyimino)-N-methylethanamide -   (2-4) trifloxystrobin -   (2-5)     (2E)-2-(methoxyimino)-N-methyl-2-(2-{[({(1E)-1-[3-(trifluoromethyl)-phenyl]ethylidene}amino)oxy]methyl}phenyl)ethanamide -   (2-6)     (2E)-2-(methoxyimino)-N-methyl-2-{2-[(E)-({1-[3-(trifluoromethyl)phenyl]-ethoxy}imino)methyl]phenyl}ethanamide -   (2-8)     5-methoxy-2-methyl-4-(2-{[({(1E)-1-[3-(trifluoromethyl)phenyl]ethylidene}-amino)oxy]methyl}phenyl)-2,4-dihydro-3H-1,2,4-triazol-3-one -   (2-11) picoxystrobin -   (2-9) kresoxim-methyl -   (2-10) dimoxystrobin -   (2-12) pyraclostrobin -   (2-13) metominostrobin -   (3-3) propiconazole -   (3-4) difenoconazole -   (3-6) cyproconazole -   (3-7) hexaconazole -   (3-8) penconazole -   (3-9) myclobutanil -   (3-10) tetraconazole -   (3-13) flusilazole -   (3-15) prothioconazole -   (3-16) fenbuconazole -   (3-17) tebuconazole -   (3-21) bitertanol -   (3-22) triadimenol -   (3-23) triadimefon -   (3-12) epoxiconazole -   (3-19) metconazole -   (3-24) fluquinconazole -   (4-1) dichlofluanid -   (4-2) tolylfluanid -   (5-1) iprovalicarb -   (5-3) benthiavalicarb -   (6-2) boscalid -   (6-5) ethaboxam -   (6-6) fenhexamid -   (6-7) carpropamid -   (6-8)     2-chloro-4-[(2-fluoro-2-methylpropanoyl)amino]-N,N-dimethylbenzamide -   (6-9) picobenzamid -   (6-10) zoxamide -   (6-11) 3,4-dichloro-N-(2-cyanophenyl)isothiazole-5-carboxamide -   (6-14) penthiopyrad -   (6-16)     N-[2-(1,3-dimethylbutyl)phenyl]-1-methyl-4-(trifluoromethyl)-1H-pyrrole-3-carboxamide -   (7-1) mancozeb -   (7-2) maneb -   (7-4) propineb -   (7-5) thiram -   (7-6) zineb -   (8-1) benalaxyl -   (8-2) furalaxyl -   (8-3) metalaxyl -   (8-4) metalaxyl-M -   (8-5) benalaxyl-M -   (9-1) cyprodinil -   (9-2) mepanipyrim -   (9-3) pyrimethanil -   (10-1)     6-chloro-5-[(3,5-dimethylisoxazol-4-yl)sulphonyl]-2,2-difluoro-5H-[1,3]dioxolo[4,5-f]-benzimidazole -   (10-3) carbendazim -   (11-1) diethofencarb -   (11-2) propamocarb -   (11-3) propamocarb-hydrochloride -   (11-4) propamocarb-fosetyl -   (12-2) captan -   (12-3) folpet -   (12-4) iprodione -   (12-5) procymidone -   (13-1) dodine -   (13-2) guazatine -   (13-3) iminoctadine triacetate -   (14-1) cyazofamid -   (14-2) prochloraz -   (14-3) triazoxide -   (15-5) dimethomorph -   (15-4) fenpropimorph -   (16-2) fludioxonil -   (17-1) fosetyl-Al -   (17-2) phosphonic acid -   (19-1) acibenzolar-S-methyl -   (19-2) chlorothalonil -   (19-3) cymoxanil -   (19-5) famoxadone -   (19-7) copper oxychloride -   (19-6) fluazinam -   (19-9) oxadixyl -   (19-10) spiroxamine -   (19-13) fenamidone -   (19-22)     2-(4-chlorophenyl)-N-{2-[3-methoxy-4-(prop-2-yn-1-yloxy)phenyl]ethyl}-2-(prop-2-yn-1-yloxy)acetamide -   (20-1) pencycuron -   (20-2) thiophanate-methyl -   (22-1)     5-chloro-N-[(1S)-2,2,2-trifluoro-1-methylethyl]-6-(2,4,6-trifluorophenyl)[1,2,4]-triazolo[1,5-a]pyrimidine-7-amine -   (22-2)     5-chloro-N-[(1R)-1,2-dimethylpropyl]-6-(2,4,6-trifluorophenyl)[1,2,4]triazolo[1,5-a]-pyrimidine-7-amine -   (22-4)     5-chloro-6-(2,4,6-trifluorophenyl)-7-(4-methylpiperidin-1-yl)[1,2,4]triazolo[1,5-a]pyrimidine -   (23-1) 2-butoxy-6-iodo-3-propylbenzopyran-4-one -   (23-2) 2-ethoxy-6-iodo-3-propylbenzopyran-4-one -   (23-3) 6-iodo-2-propoxy-3-propylbenzopyran-4-one

Very particularly preferred mixing partners are the following active compounds:

-   (2-2) fluoxastrobin -   (2-3)     (2E)-2-(2-{[6-(3-chloro-2-methylphenoxy)-5-fluoro-4-pyrimidinyl]oxy}phenyl)-2-(methoxyimino)-N-methylethanamide -   (2-4) trifloxystrobin -   (3-15) prothioconazole -   (3-17) tebuconazole -   (3-21) bitertanol -   (3-22) triadimenol -   (3-24) fluquinconazole -   (4-1) dichlofluanid -   (4-2) tolylfluanid -   (5-1) iprovalicarb -   (6-6) fenhexamid -   (6-7) carpropamid -   (6-9) picobenzamid -   (6-14) penthiopyrad -   (7-4) propineb -   (8-4) metalaxyl-M -   (8-5) benalaxyl-M -   (9-3) pyrimethanil -   (10-3) carbendazim -   (11-4) propamocarb-fosetyl -   (12-4) iprodione -   (14-2) prochloraz -   (14-3) triazoxide -   (16-2) fludioxonil -   (19-10) spiroxamine -   (19-22)     2-(4-chlorophenyl)-N-{2-[3-methoxy-4-(prop-2-yn-1-yloxy)phenyl]ethyl}-2-(prop-2-yn-1-yloxy)acetamide -   (22-4)     5-chloro-6-(2,4,6-trifluorophenyl)-7-(4-methylpiperidin-1-yl)[1,2,4]triazolo[1,5-a]pyrimidine

Preferred active compound combinations consisting of two groups of active compounds and comprising in each case at least one carboxamide of the formula (I) (group 1) and at least one active compound from the stated group (2) to (23) are described below. These combinations are the active compound combinations A to T.

Among the preferred active compound combinations A to T, emphasis is given to those comprising a carboxamide of the formula (I) (group 1)

in which R¹, R², R³ and A are as defined above.

Particular preference is given to active compound combinations A to T comprising a carboxamide of the formula (I) (group 1)

in which

-   R¹ represents hydrogen or fluorine, -   R² represents fluorine, chlorine, bromine, trifluoromethyl or     represents —CH═N—OCH₃, -   R³ represents hydrogen, fluorine or chlorine, -   A represents one of the radicals A1 or A2 below:

-   R⁶ represents methyl, -   R⁷ represents methyl, difluoromethyl or trifluoromethyl, -   R⁸ represents hydrogen or fluorine, -   R⁹ represents methyl, -   R¹⁰ represents methyl, difluoromethyl or trifluoromethyl.

Very particular preference is given to active compound combinations A to T in which the carboxamide of the formula (I) (group 1) is selected from the list below:

-   (1-1)     N-(3′,4′-dichloro-5-fluoro-1,1′-biphenyl-2-yl)-3-(difluoromethyl)-1-methyl-1H-pyrazole-4-carboxamide -   (1-2)     3-(difluoromethyl)-N-{3′-fluoro-4′-[(E)-(methoxyimino)methyl]-1,1′-biphenyl-2-yl}-1-methyl-1H-pyrazole-4-carboxamide -   (1-3)     3-(trifluoromethyl)-N-{3′-fluoro-4′-[(E)-(methoxyimino)methyl]-1,1′-biphenyl-2-yl}-1-methyl-1H-pyrazole-4-carboxamide -   (1-4)     N-(3′,4′-dichloro-1,1′-biphenyl-2-yl)-5-fluoro-1,3-dimethyl-1H-pyrazole-4-carboxamide -   (1-5)     N-(4′-chloro-3′-fluoro-1,1′-biphenyl-2-yl)-2-methyl-4-(trifluoromethyl)-1,3-thiazole-5-carboxamide -   (1-6)     N-(4′-chloro-1,1′-biphenyl-2-yl)-4-(difluoromethyl)-2-methyl-1,3-thiazole-5-carboxamide -   (1-7)     N-(4′-bromo-1,1′-biphenyl-2-yl)-4-(difluoromethyl)-2-methyl-1,3-thiazole-5-carboxamide -   (1-8)     4-(difluoromethyl)-2-methyl-N-[4′-(trifluoromethyl)-1,1′-biphenyl-2-yl]-1,3-thiazole-5-carboxamide -   (1-9)     N-(4′-chloro-3′-fluoro-1,1′-biphenyl-2-yl)-4-(difluoromethyl)-2-methyl-1,3-thiazole-5-carboxamide

Especially preferred are active compound combinations A to T in which the carboxamide of the formula (I) (group 1) is selected from the list below:

-   (1-1)     N-(3′,4′-dichloro-5-fluoro-1,1′-biphenyl-2-yl)-3-(difluoromethyl)-1-methyl-1H-pyrazole-4-carboxamide -   (1-7)     N-(4′-bromo-1,1′-biphenyl-2-yl)-4-(difluoromethyl)-2-methyl-1,3-thiazole-5-carboxamide -   (1-8)     4-(difluoromethyl)-2-methyl-N-[4′-(trifluoromethyl)-1,1′-biphenyl-2-yl]-1,3-thiazole-5-carboxamide -   (1-9)     N-(4′-chloro-3′-fluoro-1,1′-biphenyl-2-yl)-4-(difluoromethyl)-2-methyl-1,3-thiazole-5-carboxamide.

In addition to a carboxamide of the formula (I) (group 1), the active compound combinations A also comprise a strobilurin of the formula (II) (group 2)

in which A¹, L and R¹⁴ are as defined above.

Particular preference is given to active compound combinations A in which the strobilurin of the formula (II) (group 2) is selected from the list below:

-   (2-1) azoxystrobin -   (2-2) fluoxastrobin -   (2-3)     (2E)-2-(2-{[6-(3-chloro-2-methylphenoxy)-5-fluoro-4-pyrimidinyl]oxy}phenyl)-2-(methoxyimino)-N-methylethanamide -   (2-4) trifloxystrobin -   (2-5)     (2E)-2-(methoxyimino)-N-methyl-2-(2-{[({(1E)-1-[3-(trifluoromethyl)phenyl]ethylidene}-amino)oxy]methyl}phenyl)ethanamide -   (2-6)     (2E)-2-(methoxyimino)-N-methyl-2-{2-[(E)-({1-[3-(trifluoromethyl)phenyl]ethoxy}imino)-methyl]phenyl}ethanamide -   (2-7) orysastrobin -   (2-8)     5-methoxy-2-methyl-4-(2-{[({(1E)-1-[3-(trifluoromethyl)phenyl]ethylidene}amino)oxy]-methyl}phenyl)-2,4-dihydro-3H-1,2,4-triazol-3-one -   (2-9) kresoxim-methyl -   (2-10) dimoxystrobin -   (2-11) picoxystrobin -   (2-12) pyraclostrobin -   (2-13) metominostrobin

Very particular preference is given to active compound combinations A in which the strobilurin of the formula (II) (group 2) is selected from the list below:

-   (2-1) azoxystrobin -   (2-2) fluoxastrobin -   (2-3)     (2E)-2-(2-{[6-(3-chloro-2-methylphenoxy)-5-fluoro-4-pyrimidinyl]oxy}phenyl)-2-(methoxyimino)-N-methylethanamide -   (2-4) trifloxystrobin -   (2-12) pyraclostrobin -   (2-9) kresoxim-methyl -   (2-10) dimoxystrobin -   (2-11) picoxystrobin -   (2-13) metominostrobin

Emphasis is given to the active compound combinations A listed in Table 1 below:

TABLE 1 Active compound combinations A No. Carboxamide of the formula (I) Strobilurin of the formula (II) A-1 (1-1) N-(3′,4′-dichloro-5-fluoro-1,1′-biphenyl-2-yl)-3- (2-1) azoxystrobin (difluoromethyl)-1-methyl-1H-pyrazole-4-carboxamide A-2 (1-1) N-(3′,4′-dichloro-5-fluoro-1,1′-biphenyl-2-yl)-3- (2-2) fluoxastrobin (difluoromethyl)-1-methyl-1H-pyrazole-4-carboxamide A-3 (1-1) N-(3′,4′-dichloro-5-fluoro-1,1′-biphenyl-2-yl)- (2-3) (2E)-2-(2-{[6-(3-chloro-2- 3-(difluoromethyl)-1-methyl-1H-pyrazole-4-carboxamide methylphenoxy)-5-fluoro-4- pyrimidinyl]oxy}phenyl)-2- (methoxyimino)-N-methylethanamide A-4 (1-1) N-(3′,4′-dichloro-5-fluoro-1,1′-biphenyl-2-yl)-3- (2-4) trifloxystrobin (difluoromethyl)-1-methyl-1H-pyrazole-4-carboxamide A-5 (1-1) N-(3′,4′-dichloro-5-fluoro-1,1′-biphenyl-2-yl)-3- (2-12) pyraclostrobin (difluoromethyl)-1-methyl-1H-pyrazole-4-carboxamide A-6 (1-2) 3-(difluoromethyl)-N-{3′-fluoro-4′-[(E)- (2-1) azoxystrobin (methoxyimino)methyl]-1,1′-biphenyl-2-yl}-1-methyl- 1H-pyrazole-4-carboxamide A-7 (1-2) 3-(difluoromethyl)-N-{3′-fluoro-4′-[(E)- (2-2) fluoxastrobin (methoxyimino)methyl]-1,1′-biphenyl-2-yl}-1-methyl- 1H-pyrazole-4-carboxamide A-8 (1-2) 3-(difluoromethyl)-N-{3′-fluoro-4′-[(E)- (2-3) (2E)-2-(2-{[6-(3-chloro-2- (methoxyimino)methyl]-1,1′-biphenyl-2-yl}-1-methyl- methylphenoxy)-5-fluoro-4- 1H-pyrazole-4-carboxamide pyrimidinyl]oxy}phenyl)-2- (methoxyimino)-N-methylethanamide A-9 (1-2) 3-(difluoromethyl)-N-{3′-fluoro-4′-[(E)- (2-4) trifloxystrobin (methoxyimino)methyl]-1,1′-biphenyl-2-yl}-1-methyl- 1H-pyrazole-4-carboxamide A-10 (1-2) 3-(difluoromethyl)-N-{3′-fluoro-4′-[(E)- (2-12) pyraclostrobin (methoxyimino)methyl]-1,1′-biphenyl-2-yl}-1-methyl- 1H-pyrazole-4-carboxamide A-11 (1-3) 3-(trifluoromethyl)-N-{3′-fluoro-4′-[(E)- (2-1) azoxystrobin (methoxyimino)methyl]-1,1′-biphenyl-2-yl}-1-methyl- 1H-pyrazole-4-carboxamide A-12 (1-3) 3-(trifluoromethyl)-N-{3′-fluoro-4′-[(E)- (2-2) fluoxastrobin (methoxyimino)methyl]-1,1′-biphenyl-2-yl}-1-methyl- 1H-pyrazole-4-carboxamide A-13 (1-3) 3-(trifluoromethyl)-N-{3′-fluoro-4′-[(E)- (2-3) (2E)-2-(2-{[6-(3-chloro-2- (methoxyimino)methyl]-1,1′-biphenyl-2-yl}-methyl- methylphenoxy)-5-fluoro-4- 1H-pyrazole-4-carboxamide pyrimidinyl]oxy}phenyl)-2- (methoxyimino)-N-methylethanamide A-14 (1-3) 3-(trifluoromethyl)-N-{3′-fluoro-4′-[(E)- (2-4) trifloxystrobin (methoxyimino)methyl]-1,1′-biphenyl-2-yl}-methyl- 1H-pyrazole-4-carboxamide A-15 (1-3) 3-(trifluoromethyl)-N-{3′-fluoro-4′-[(E)- (2-12) pyraclostrobin (methoxyimino)methyl]-1,1′-biphenyl-2-yl}-methyl- 1H-pyrazole-4-carboxamide A-16 (1-4) N-(3′,4′-dichloro-1,1′-biphenyl-2-yl)-5-fluoro- (2-1) azoxystrobin 1,3-dimethyl-1H-pyrazole-4-carboxamide A-17 (1-4) N-(3′,4′-dichloro-1,1′-biphenyl-2-yl)-5-fluoro- (2-2) fluoxastrobin 1,3-dimethyl-1H-pyrazole-4-carboxamide A-18 (1-4) N-(3′,4′-dichloro-1,1′-biphenyl-2-yl)-5-fluoro- (2-3) (2E)-2-(2-{[6-(3-chloro-2- 1,3-dimethyl-1H-pyrazole-4-carboxamide methylphenoxy)-5-fluoro-4- pyrimidinyl]oxy}phenyl)-2- (methoxyimino)-N-methylethanamide A-19 (1-4) N-(3′,4′-dichloro-1,1′-biphenyl-2-yl)-5-fluoro- (2-4) trifloxystrobin 1,3-dimethyl-1H-pyrazole-4-carboxamide A-20 (1-4) N-(3′,4′-dichloro-1,1′-biphenyl-2-yl)-5-fluoro- (2-12) pyraclostrobin 1,3-dimethyl-1H-pyrazole-4-carboxamide A-21 (1-5) N-(4′-chloro-3′-fluoro-1,1′-biphenyl-2-yl)-2-methyl- (2-1) azoxystrobin 4-(trifluoromethyl)-1,3-thiazole-5-carboxamide A-22 (1-5) N-(4′-chloro-3′-fluoro-1,1′-biphenyl-2-yl)-2-methyl- (2-2) fluoxastrobin 4-(trifluoromethyl)-1,3-thiazole-5-carboxamide A-23 (1-5) N-(4′-chloro-3′-fluoro-1,1′-biphenyl-2-yl)-2-methyl- (2-3) (2E)-2-(2-{[6-(3-chloro-2- 4-(trifluoromethyl)-1,3-thiazole-5-carboxamide methylphenoxy)-5-fluoro-4- pyrimidinyl]oxy}phenyl)-2- (methoxyimino)-N-methylethanamide A-24 (1-5) N-(4′-chloro-3′-fluoro-1,1′-biphenyl-2-yl)-2-methyl- (2-4) trifloxystrobin 4-(trifluoromethyl)-1,3-thiazole-5-carboxamide A-25 (1-5) N-(4′-chloro-3′-fluoro-1,1′-biphenyl-2-yl)-2-methyl- (2-12) pyraclostrobin 4-(trifluoromethyl)-1,3-thiazole-5-carboxamide A-26 (1-6) N-(4′-chloro-1,1′-biphenyl-2-yl)-4-(difluoromethyl)- (2-1) azoxystrobin 2-methyl-1,3-thiazole-5-carboxamide A-27 (1-6) N-(4′-chloro-1,1′-biphenyl-2-yl)-4-(difluoromethyl)- (2-2) fluoxastrobin 2-methyl-1,3-thiazole-5-carboxamide A-28 (1-6) N-(4′-chloro-1,1′-biphenyl-2-yl)-4-(difluoro-methyl)- (2-3) (2E)-2-(2-{[6-(3-chloro-2- 2-methyl-1,3-thiazole-5-carboxamide methylphenoxy)-5-fluoro-4- pyrimidinyl]oxy}phenyl)-2- o(methxyimino)-N-methylethanamide A-29 (1-6) N-(4′-chloro-1,1′-biphenyl-2-yl)-4-(difluoromethyl)- (2-4) trifloxystrobin 2-methyl-1,3-thiazole-5-carboxamide A-30 (1-6) N-(4′-chloro-1,1′-biphenyl-2-yl)-4-(difluoromethyl)- (2-12) pyraclostrobin 2-methyl-1,3-thiazole-5-carboxamide A-31 (1-7) N-(4′-bromo-1,1′-biphenyl-2-yl)-4-(difluoromethyl)- (2-1) azoxystrobin 2-methyl-1,3-thiazole-5-carboxamide A-32 (1-7) N-(4′-bromo-1,1′-biphenyl-2-yl)-4-(difluoromethyl)- (2-2) fluoxastrobin 2-methyl-1,3-thiazole-5-carboxamide A-33 (1-7) N-(4′-bromo-1,1′-biphenyl-2-yl)-4-(difluoromethyl)- (2-3) (2E)-2-(2-{[6-(3-chloro-2- 2-methyl-1,3-thiazole-5-carboxamide methylphenoxy)-5-fluoro-4- pyrimidinyl]oxy}phenyl)-2- (methoxyimino)-N-methylethanamide A-34 (1-7) N-(4′-bromo-1,1′-biphenyl-2-yl)-4-(difluoromethyl)- (2-4) trifloxystrobin 2-methyl-1,3-thiazole-5-carboxamide A-35 (1-7) N-(4′-bromo-1,1′-biphenyl-2-yl)-4-(difluoromethyl)- (2-12) pyraclostrobin 2-methyl-1,3-thiazole-5-carboxamide A-36 (1-8) 4-(difluoromethyl)-2-methyl-N-[4′-(trifluoromethyl)- (2-1) azoxystrobin 1,1′-biphenyl-2-yl]-1,3-thiazole-5-carboxamide A-37 (1-8) 4-(difluoromethyl)-2-methyl-N-[4′-(trifluoromethyl)- (2-2) fluoxastrobin 1,1′-biphenyl-2-yl]-1,3-thiazole-5-carboxamide A-38 (1-8) 4-(difluoromethyl)-2-methyl-N-[4′-(trifluoromethyl)- (2-3) (2E)-2-(2-{[6-(3-chloro-2- 1,1′-biphenyl-2-yl]-1,3-thiazole-5-carboxamide methylphenoxy)-5-fluoro-4- pyrimidinyl]oxy}phenyl)-2- (methoxyimino)-N-methylethanamide A-39 (1-8) 4-(difluoromethyl)-2-methyl-N-[4′-(trifluoromethyl)- (2-4) trifloxystrobin 1,1′-biphenyl-2-yl]-1,3-thiazole-5-carboxamide A-40 (1-8) 4-(difluoromethyl)-2-methyl-N-[4′-(trifluoromethyl)- (2-12) pyraclostrobin 1,1′-biphenyl-2-yl]-1,3-thiazole-5-carboxamide A-41 (1-1) N-(3′,4′-dichloro-5-fluoro-1,1′-biphenyl-2-yl)-3- (2-9) kresoxim-methyl (difluoromethyl)-1-methyl-1H-pyrazole-4-carboxamide A-42 (1-1) N-(3′,4′-dichloro-5-fluoro-1,1′-biphenyl-2-yl)-3- (2-10) dimoxystrobin (difluoromethyl)-1-methyl-1H-pyrazole-4-carboxamide A-43 (1-1) N-(3′,4′-dichloro-5-fluoro-1,1′-biphenyl-2-yl)-3- (2-11) picoxystrobin (difluoromethyl)-1-methyl-1H-pyrazole-4-carboxamide A-44 (1-1) N-(3′,4′-dichloro-5-fluoro-1,1′-biphenyl-2-yl)-3- (2-13) metominostrobin (difluoromethyl)-1-methyl-1H-pyrazole-4-carboxamide A-45 (1-7) N-(4′-bromo-1,1′-biphenyl-2-yl)-4-(difluoromethyl)- (2-9) kresoxim-methyl 2-methyl-1,3-thiazole-5-carboxamide A-46 (1-7) N-(4′-bromo-1,1′-biphenyl-2-yl)-4-(difluoromethyl)- (2-10) dimoxystrobin 2-methyl-1,3-thiazole-5-carboxamide A-47 (1-7) N-(4′-bromo-1,1′-biphenyl-2-yl)-4-(difluoromethyl)- (2-11) picoxystrobin 2-methyl-1,3-thiazole-5-carboxamide A-48 (1-7) N-(4′-bromo-1,1′-biphenyl-2-yl)-4-(difluoromethyl)- (2-13) metominostrobin 2-methyl-1,3-thiazole-5-carboxamide A-49 (1-8) 4-(difluoromethyl)-2-methyl-N-[4′-(trifluoromethyl)- (2-9) kresoxim-methyl 1,1′-biphenyl-2-yl]-1,3-thiazole-5-carboxamide A-50 (1-8) 4-(difluoromethyl)-2-methyl-N-[4′-(trifluoromethyl)- (2-10) dimoxystrobin 1,1′-biphenyl-2-yl]-1,3-thiazole-5-carboxamide A-51 (1-8) 4-(difluoromethyl)-2-methyl-N-[4′-(trifluoromethyl)- (2-11) picoxystrobin 1,1′-biphenyl-2-yl]-1,3-thiazole-5-carboxamide A-52 (1-8) 4-(difluoromethyl)-2-methyl-N-[4′-(trifluoromethyl)- (2-13) metominostrobin 1,1′-biphenyl-2-yl]-1,3-thiazole-5-carboxamide A-53 (1-9) N-(4′-chloro-3′-fluoro-1,1′-biphenyl-2-yl)-4- (2-9) kresoxim-methyl (difluoromethyl)-2-methyl-1,3-thiazole-5-carboxamide A-54 (1-9) N-(4′-chloro-3′-fluoro-1,1′-biphenyl-2-yl)-4- (2-10) dimoxystrobin (difluoromethyl)-2-methyl-1,3-thiazole-5-carboxamide A-55 (1-9) N-(4′-chloro-3′-fluoro-1,1′-biphenyl-2-yl)-4- (2-11) picoxystrobin (difluoromethyl)-2-methyl-1,3-thiazole-5-carboxamide A-56 (1-9) N-(4′-chloro-3′-fluoro-1,1′-biphenyl-2-yl)-4- (2-13) metominostrobin (difluoromethyl)-2-methyl-1,3-thiazole-5-carboxamide A-57 (1-9) N-(4′-chloro-3′-fluoro-1,1′-biphenyl-2-yl)-4- (2-1) azoxystrobin (difluoromethyl)-2-methyl-1,3-thiazole-5-carboxamide A-58 (1-9) N-(4′-chloro-3′-fluoro-1,1′-biphenyl-2-yl)-4- (2-2) fluoxastrobin (difluoromethyl)-2-methyl-1,3-thiazole-5-carboxamide A-59 (1-9) N-(4′-chloro-3′-fluoro-1,1′-biphenyl-2-yl)-4- (2-3) (2E)-2-(2-{[6-(3-chloro-2- (difluoromethyl)-2-methyl-1,3-thiazole-5-carboxamide methylphenoxy)-5-fluoro-4- pyrimidinyl]oxy{phenyl)-2- (methoxyimino)-N-methylethanamide A-60 (1-9) N-(4′-chloro-3′-fluoro-1,1′-biphenyl-2-yl)-4- (2-4) trifloxystrobin (difluoromethyl)-2-methyl-1,3-thiazole-5-carboxamide A-61 (1-9) N-(4′-chloro-3′-fluoro-1,1′-biphenyl-2-yl)-4- (2-12) pyraclostrobin (difluoromethyl)-2-methyl-1,3-thiazole-5-carboxamide

In addition to a carboxamide of the formula (I) (group 1), the active compound combinations B also comprise a triazole of the formula (III) (group 3)

in which Q, m, R¹⁶, R¹⁷, A⁴, A⁵, R¹⁸ and R¹⁹ are as defined above.

Preference is given to active compound combinations B in which the triazole of the formula (III) (group 3) is selected from the list below:

-   (3-1) azaconazole -   (3-2) etaconazole -   (3-3) propiconazole -   (3-4) difenoconazole -   (3-5) bromuconazole -   (3-6) cyproconazole -   (3-7) hexaconazole -   (3-8) penconazole -   (3-9) myclobutanil -   (3-10) tetraconazole -   (3-11) flutriafol -   (3-12) epoxiconazole -   (3-13) flusilazole -   (3-14) simeconazole -   (3-15) prothioconazole -   (3-16) fenbuconazole -   (3-17) tebuconazole -   (3-18) ipconazole -   (3-19) metconazole -   (3-20) triticonazole -   (3-21) bitertanol -   (3-22) triadimenol -   (3-23) triadimefon -   (3-24) fluquinconazole -   (3-25) quinconazole

Particular preference is given to active compound combinations B in which the triazole of the formula (III) (group 3) is selected from the list below:

-   (3-3) propiconazole -   (3-4) difenoconazole -   (3-6) cyproconazole -   (3-7) hexaconazole -   (3-15) prothioconazole -   (3-17) tebuconazole -   (3-21) bitertanol -   (3-19) metconazole -   (3-22) triadimenol -   (3-24) fluquinconazole

Emphasis is given to the active compound combinations B listed in Table 2 below:

TABLE 2 Active compound combinations B Triazole of the No. Carboxamide of the formula (I) formula (III) B-1 (1-1) N-(3′,4′-dichloro-5-fluoro-1,1′-biphenyl-2-yl)-3- (3-3) propiconazole (difluoromethyl)-1-methyl-1H-pyrazole-4-carboxamide B-2 (1-1) N-(3′,4′-dichloro-5-fluoro-1,1′-biphenyl-2-yl)-3- (3-6) cyproconazole (difluoromethyl)-1-methyl-1H-pyrazole-4-carboxamide B-3 (1-1) N-(3′,4′-dichloro-5-fluoro-1,1′-biphenyl-2-yl)-3- (3-15) prothioconazole (difluoromethyl)-1-methyl-1H-pyrazole-4-carboxamide B-4 (1-1) N-(3′,4′-dichloro-5-fluoro-1,1′-biphenyl-2-yl)-3- (3-17) tebuconazole (difluoromethyl)-1-methyl-1H-pyrazole-4-carboxamide B-5 (1-1) N-(3′,4′-dichloro-5-fluoro-1,1′-biphenyl-2-yl)-3- (3-21) bitertanol (difluoromethyl)-1-methyl-1H-pyrazole-4-carboxamide B-6 (1-2) 3-(difluoromethyl)-N-{3′-fluoro-4′-[(E)-(methoxyimino)- (3-3) propiconazole methyl]-1,1′-biphenyl-2-yl}-1-methyl-1H-pyrazole-4- carboxamide B-7 (1-2) 3-(difluoromethyl)-N-{3′-fluoro-4′-[(E)-(methoxyimino)- (3-6) cyproconazole methyl]-1,1′-biphenyl-2-yl}-1-methyl-1H-pyrazole-4- carboxamide B-8 (1-2) 3-(difluoromethyl)-N-{3′-fluoro-4′-[(E)-(methoxyimino)- (3-15) prothioconazole methyl]-1,1′-biphenyl-2-yl}-1-methyl-1H-pyrazole-4- carboxamide B-9 (1-2) 3-(difluoromethyl)-N-{3′-fluoro-4′-[(E)-(methoxyimino)- (3-17) tebuconazole methyl]-1,1′-bipheny1-2-yl}-1-methyl-1H-pyrazole-4- carboxamide B- 10 (1-2) 3-(difluoromethyl)-N-{3′-fluoro-4′-[(E)-(methoxyimino)- (3-21) bitertanol methyl]-1,1′-biphenyl-2-yl}-1-methyl-1H-pyrazole-4- carboxamide B- 11 (1-3) 3-(trifluoromethyl)-N-{3′-fluoro-4′-[(E)-(methoxyimino)- (3-3) propiconazole methyl]-1,1′-biphenyl-2-yl}-1-methyl-1H-pyrazole-4- carboxamide B- 12 (1-3) 3-(trifluoromethyl)-N-{3′-fluoro-4′-[(E)-(methoxyimino)- (3-6) cyproconazole methyl]-1,1′-biphenyl-2-yl}-1-methyl-1H-pyrazole-4- carboxamide B-13 (1-3) 3-(trifluoromethyl)-N-{3′-fluoro-4′-[(E)-(methoxyimino)- (3-15) prothioconazole methyl]-1,1′-biphenyl-2-yl}-1-methyl-1H-pyrazole-4- carboxamide B-14 (1-3) 3-(trifluoromethyl)-N-{3′-fluoro-4′-[(E)-(methoxyimino)- (3-17) tebuconazole methyl]-1,1′-biphenyl-2-yl}-1-methyl-1H-pyrazole-4- carboxamide B-15 (1-3) 3-(trifluoromethyl)-N-{3′-fluoro-4′-[(E)-(methoxyimino)- (3-21) bitertanol methyl]-1,1′-biphenyl-2-yl}-1-methyl-1H-pyrazole-4- carboxamide B-16 (1-4) N-(3′,4′-dichloro-1,1′-biphenyl-2-yl)-5-fluoro-1,3- (3-3) propiconazole dimethyl-1H-pyrazole-4-carboxamide B-17 (1-4) N-(3′,4′-dichloro-1,1′-biphenyl-2-yl)-5-fluoro-1,3- (3-6) cyproconazole dimethyl-1H-pyrazole-4-carboxamide B-18 (1-4) N-(3′,4′-dichloro-1,1′-biphenyl-2-yl)-5-fluoro-1,3- (3-15) prothioconazole dimethyl-1H-pyrazole-4-carboxamide B-19 (1-4) N-(3′,4′-dichloro-1,1′-biphenyl-2-yl)-5-fluoro-1,3- (3-17) tebuconazole dimethyl-1H-pyrazole-4-carboxamide B-20 (1-4) N-(3′,4′-dichloro-1,1′-biphenyl-2-yl)-5-fluoro-1,3- (3-21) bitertanol dimethyl-1H-pyrazole-4-carboxamide B-21 (1-5) N-(4′-chloro-3′-fluoro-1,1′-biphenyl-2-yl)-2-methyl- (3-3) propiconazole 4-(trifluoromethyl)-1,3-thiazole-5-carboxamide B-22 (1-5) N-(4′-chloro-3′-fluoro-1,1′-biphenyl-2-yl)-2-methyl- (3-6) cyproconazole 4-(trifluoromethyl)-1,3-thiazole-5-carboxamide B-23 (1-5) N-(4′-chloro-3′-fluoro-1,1′-biphenyl-2-yl)-2-methyl- (3-15) prothioconazole 4-(trifluoromethyl)-1,3-thiazole-5-carboxamide B-24 (1-5) N-(4′-chloro-3′-fluoro-1,1′-biphenyl-2-yl)-2-methyl- (3-17) tebuconazole 4-(trifluoromethyl)-1,3-thiazole-5-carboxamide B-25 (1-5) N-(4′-chloro-3′-fluoro-1,1′-biphenyl-2-yl)-2-methyl- (3-21) bitertanol 4-(trifluoromethyl)-1,3-thiazole-5-carboxamide B-26 (1-6) N-(4′-chloro-1,1′-biphenyl-2-yl)-4-(difluoromethyl)- (3-3) propiconazole 2-methyl-1,3-thiazole-5-carboxamide B-27 (1-6) N-(4′-chloro-1,1′-biphenyl-2-yl)-4-(difluoromethyl)- (3-6) cyproconazole 2-methyl-1,3-thiazole-5-carboxamide B-28 (1-6) N-(4′-chloro-1,1′-biphenyl-2-yl)-4-(difluoromethyl)- (3-15) prothioconazole 2-methyl-1,3-thiazole-5-carboxamide B-29 (1-6) N-(4′-chloro-1,1′-biphenyl-2-yl)-4-(difluoromethyl)- (3-17) tebuconazole 2-methyl-1,3-thiazole-5-carboxamide B-30 (1-6) N-(4′-chloro-1,1′-biphenyl-2-yl)-4-(difluoromethyl)- (3-21) bitertanol 2-methyl-1,3-thiazole-5-carboxamide B-31 (1-7) N-(4′-bromo-1,1′-biphenyl-2-yl)-4-(difluoromethyl)- (3-3) propiconazole 2-methyl-1,3-thiazole-5-carboxamide B-32 (1-7) N-(4′-bromo-1,1′-biphenyl-2-yl)-4-(difluoromethyl)- (3-6) cyproconazole 2-methyl-1,3-thiazole-5-carboxamide B-33 (1-7) N-(4′-bromo-1,1′-biphenyl-2-yl)-4-(difluoromethyl)- (3-15) prothioconazole 2-methyl-1,3-thiazole-5-carboxamide B-34 (1-7) N-(4′-bromo-1,1′-biphenyl-2-yl)-4-(difluoromethyl)- (3-17) tebuconazole 2-methyl-1,3-thiazole-5-carboxamide B-35 (1-7) N-(4′-bromo-1,1′-biphenyl-2-yl)-4-(difluoromethyl)- (3-21) bitertanol 2-methyl-1,3-thiazole-5-carboxamide B-36 (1-8) 4-(difluoromethyl)-2-methyl-N-[4′-(trifluoromethyl)-1,1′- (3-3) propiconazole biphenyl-2-yl]-1,3-thiazole-5-carboxamide B-37 (1-8) 4-(difluoromethyl)-2-methyl-N-[4′-(trifluoromethyl)-1,1′- (3-6) cyproconazole biphenyl-2-yl]-1,3-thiazole-5-carboxamide B-38 (1-8) 4-(difluoromethyl)-2-methyl-N-[4′-(trifluoromethyl)-1,1′- (3-15) prothioconazole biphenyl-2-yl]-1,3-thiazole-5-carboxamide B-39 (1-8) 4-(difluoromethyl)-2-methyl-N-[4′-(trifluoromethyl)-1,1′- (3-17) tebuconazole biphenyl-2-yl]-1,3-thiazole-5-carboxamide B-40 (1-8) 4-(difluoromethyl)-2-methyl-N-[4′-(trifluoromethyl)-1,1′- (3-21) bitertanol biphenyl-2-yl]-1,3-thiazole-5-carboxamide B-41 (1-1) N-(3′,4′-dichloro-5-fluoro-1,1′-biphenyl-2-yl)-3- (3-4) difenoconazole (difluoromethyl)-1-methyl-1H-pyrazole-4-carboxamide B-42 (1-1) N-(3′,4′-dichloro-5-fluoro-1,1′-biphenyl-2-yl)-3- (3-7) hexaconazole (difluoromethyl)-1-methyl-1H-pyrazole-4-carboxamide B-43 (1-1) N-(3′,4′-dichloro-5-fluoro-1,1′-biphenyl-2-yl)-3- (3-19) metconazole (difluoromethyl)-1-methyl-1H-pyrazole-4-carboxamide B-44 (1-1) N-(3′,4′-dichloro-5-fluoro-1,1′-biphenyl-2-yl)-3- (3-22) triadimenol (difluoromethyl)-1-methyl-1H-pyrazole-4-carboxamide B-45 (1-1) N-(3′,4′-dichloro-5-fluoro-1,1′-biphenyl-2-yl)-3- (3-24) fluquinconazole (difluoromethyl)-1-methyl-1H-pyrazole-4-carboxamide B-46 (1-7) N-(4′-bromo-1,1′-biphenyl-2-yl)-4-(difluoromethyl)- (3-4) difenoconazole 2-methyl-1,3-thiazole-5-carboxamide B-47 (1-7) N-(4′-bromo-1,1′-biphenyl-2-yl)-4-(difluoromethyl)- (3-7) hexaconazole 2-methyl-1,3-thiazole-5-carboxamide B-48 (1-7) N-(4′-bromo-1,1′-biphenyl-2-yl)-4-(difluoromethyl)- (3-19) metconazole 2-methyl-1,3-thiazole-5-carboxamide B-49 (1-7) N-(4′-bromo-1,1′-biphenyl-2-yl)-4-(difluoromethyl)- (3-22) triadimenol 2-methyl-1,3-thiazole-5-carboxamide B-50 (1-7) N-(4′-bromo-1,1′-biphenyl-2-yl)-4-(difluoromethyl)- (3-24) fluquinconazole 2-methyl-1,3-thiazole-5-carboxamide B-51 (1-8) 4-(difluoromethyl)-2-methyl-N-[4′-(trifluoromethyl)-1,1′- (3-4) difenoconazole biphenyl-2-yl]-1,3-thiazole-5-carboxamide B-52 (1-8) 4-(difluoromethyl)-2-methyl-N-[4′-(trifluoromethyl)-1,1′- (3-7) hexaconazole biphenyl-2-yl]-1,3-thiazole-5-carboxamide B-53 (1-8) 4-(difluoromethyl)-2-methyl-N-[4′-(trifluoromethyl)-1,1′- (3-19) metconazole biphenyl-2-yl]-1,3-thiazole-5-carboxamide B-54 (1-8) 4-(difluoromethyl)-2-methyl-N-[4′-(trifluoromethyl)-1,1′- (3-22) triadimenol biphenyl-2-yl]-1,3-thiazole-5-carboxamide B-55 (1-8) 4-(difluoromethyl)-2-methyl-N-[4′-(trifluoromethyl)-1,1′- (3-24) fluquinconazole biphenyl-2-yl]-1,3-thiazole-5-carboxamide B-56 (1-9) N-(4′-chloro-3′-fluoro-1,1′-biphenyl-2-yl)-4- (3-4) difenoconazole (difluoromethyl)-2-methyl-1,3-thiazole-5-carboxamide B-57 (1-9) N-(4′-chloro-3′-fluoro-1,1′-biphenyl-2-yl)-4- (3-7) hexaconazole (difluoromethyl)-2-methyl-1,3-thiazole-5-carboxamide B-58 (1-9) N-(4′-chloro-3′-fluoro-1,1′-biphenyl-2-yl)-4- (3-19) metconazole (difluoromethyl)-2-methyl-1,3-thiazole-5-carboxamide B-59 (1-9) N-(4′-chloro-3′-fluoro-1,1′-biphenyl-2-yl)-4- (3-22) triadimenol (difluoromethyl)-2-methyl-1,3-thiazole-5-carboxamide B-60 (1-9) N-(4′-chloro-3′-fluoro-1,1′-biphenyl-2-yl)-4- (3-24) fluquinconazole (difluoromethyl)-2-methyl-1,3-thiazole-5-carboxamide B-61 (1-9) N-(4′-chloro-3′-fluoro-1,1′-biphenyl-2-yl)-4- (3-3) propiconazole (difluoromethyl)-2-methyl-1,3-thiazole-5-carboxamide B-62 (1-9) N-(4′-chloro-3′-fluoro-1,1′-biphenyl-2-yl)-4- (3-6) cyproconazole (difluoromethyl)-2-methyl-1,3-thiazole-5-carboxamide B-63 (1-9) N-(4′-chloro-3′-fluoro-1,1′-biphenyl-2-yl)-4- (3-15) prothioconazole (difluoromethyl)-2-methyl-1,3-thiazole-5-carboxamide B-64 (1-9) N-(4′-chloro-3′-fluoro-1,1′-biphenyl-2-yl)-4- (3-17) tebuconazole (difluoromethyl)-2-methyl-1,3-thiazole-5-carboxamide B-65 (1-9) N-(4′-chloro-3′-fluoro-1,1′-biphenyl-2-yl)-4- (3-21) bitertanol (difluoromethyl)-2-methyl-1,3-thiazole-5-carboxamide

In addition to a carboxamide of the formula (I) (group 1), the active compound combinations C also comprise a sulphonamide of the formula (IV) (group 4)

in which R²² is as defined above.

Preference is given to active compound combinations C in which the sulphonamide of the formula (IV) (group 4) is selected from the following list:

-   (4-1) dichlofluanid -   (4-2) tolylfluanid

Emphasis is given to the active compound combinations C listed in Table 3 below:

TABLE 3 Active compound combinations C Sulphenamide of No. Carboxamide of the formula (I) the formula (IV) C-1 (1-1) N-(3′,4′-dichloro-5-fluoro-1,1′- (4-1) dichlofluanid biphenyl-2-yl)-3-(difluoromethyl)-1- methyl-1H-pyrazole-4-carboxamide C-2 (1-1) N-(3′,4′-dichloro-5-fluoro-1,1′- (4-2) tolylfluanid biphenyl-2-yl)-3-(difluoromethyl)-1- methyl-1H-pyrazole-4-carboxamide C-3 (1-7) N-(4′-bromo-1,1′-biphenyl-2-yl)- (4-1) dichlofluanid 4-(difluoromethyl)-2-methyl-1,3- thiazole-5-carboxamide C-4 (1-7) N-(4′-bromo-1,1′-biphenyl-2-yl)- (4-2) tolylfluanid 4-(difluoromethyl)-2-methyl-1,3- thiazole-5-carboxamide C-5 (1-8) 4-(difluoromethyl)-2-methyl-N- (4-1) dichlofluanid [4′-(trifluoromethyl)-1,1′-biphenyl-2-yl]- 1,3-thiazole-5-carboxamide C-6 (1-8) 4-(difluoromethyl)-2-methyl-N- (4-2) tolylfluanid [4′-(trifluoromethyl)-1,1′-biphenyl-2-yl]- 1,3-thiazole-5-carboxamide C-7 (1-9) N-(4′-chloro-3′-fluoro-1,1′-biphenyl- (4-1) dichlofluanid 2-yl)-4-(difluoromethyl)-2-methyl-1,3- thiazole-5-carboxamide C-8 (1-9) N-(4′-chloro-3′-fluoro-1,1′-biphenyl- (4-2) tolylfluanid 2-yl)-4-(difluoromethyl)-2-methyl-1,3- thiazole-5-carboxamide

In addition to a carboxamide of the formula (I) (group 1), the active compound combinations D also comprise a valinamide (group 5) selected from

-   (5-1) iprovalicarb -   (5-2)     N′-[2-(4-{[3-(4-chlorophenyl)-2-propynyl]oxy}-3-methoxyphenyl)ethyl]-N²-(methyl-sulphonyl)-D-valinamide -   (5-3) benthiavalicarb

Preference is given to active compound combinations D in which the valinamide (group 5) is selected from the following list:

-   (5-1) iprovalicarb -   (5-3) benthiavalicarb

Emphasis is given to the active compound combinations D listed in Table 4 below:

TABLE 4 Active compound combinations D No. Carboxamide of the formula (I) Valinamide D-1 (1-1) N-(3′,4′-dichloro-5-fluoro-1,1′-biphenyl-2-yl)-3-(difluoromethyl)- (5-1) iprovalicarb 1-methyl-1H-pyrazole-4-carboxamide D-2 (1-1) N-(3′,4′-dichloro-5-fluoro-1,1′-biphenyl-2-yl)-3-(difluoromethyl)- (5-2) benthiavalicarb 1-methyl-1H-pyrazole-4-carboxamide D-3 (1-7) N-(4′-bromo-1,1′-biphenyl-2-yl)-4-(difluoromethyl)-2-methyl-1,3- (5-1) iprovalicarb thiazole-5-carboxamide D-4 (1-7) N-(4′-bromo-1,1′-biphenyl-2-yl)-4-(difluoromethyl)-2-methyl-1,3- (5-2) benthiavalicarb thiazole-5-carboxamide D-5 (1-8) 4-(difluoromethyl)-2-methyl-N-[4′-(trifluoromethyl)-1,1′- (5-1) iprovalicarb biphenyl-2-yl]-1,3-thiazole-5-carboxamide D-6 (1-8) 4-(difluoromethyl)-2-methyl-N-[4′-(trifluoromethyl)-1,1′- (5-2) benthiavalicarb biphenyl-2-yl]-1,3-thiazole-5-carboxamide D-7 (1-9) N-(4′-chloro-3′-fluoro-1,1′-biphenyl-2-yl)-4-(difluoromethyl)-2- (5-1) iprovalicarb methyl-1,3-thiazole-5-carboxamide D-8 (1-9) N-(4′-chloro-3′-fluoro-1,1′-biphenyl-2-yl)-4-(difluoromethyl)-2- (5-2) benthiavalicarb methyl-1,3-thiazole-5-carboxamide

In addition to a carboxamide of the formula (I) (group 1), the active compound combinations E also comprise a carboxamide of the formula (V) (group 6)

in which X, Y and Z are as defined above.

Preference is given to active compound combinations E in which the carboxamide of the formula (V) (group 6) is selected from the list below:

-   (6-1) 2-chloro-N-(1,1,3-trimethylindan-4-yl)nicotinamide -   (6-2) boscalid -   (6-3) furametpyr -   (6-4)     N-(3-p-tolylthiophen-2-yl)-1-methyl-3-trifluoromethyl-1H-pyrazole-4-carboxamide -   (6-5) ethaboxam -   (6-6) fenhexamid -   (6-7) carpropamid -   (6-8)     2-chloro-4-(2-fluoro-2-methylpropionylamino)-N,N-dimethylbenzamide -   (6-9) picobenzamid -   (6-10) zoxamide -   (6-11) 3,4-dichloro-N-(2-cyanophenyl)isothiazole-5-carboxamide -   (6-12) carboxin -   (6-13) tiadinil -   (6-14) penthiopyrad -   (6-15) silthiofam -   (6-16)     N-[2-(1,3-dimethylbutyl)phenyl]-1-methyl-4-(trifluoromethyl)-1H-pyrrole-3-carboxamide     Particular preference is given to active compound combinations E in     which the carboxamide of the formula (V) (group 6) is selected from     the list below: -   (6-2) boscalid -   (6-5) ethaboxam -   (6-6) fenhexamid -   (6-7) carpropamid -   (6-8)     2-chloro-4-(2-fluoro-2-methylpropionylamino)-N,N-dimethylbenzamide -   (6-9) picobenzamid -   (6-10) zoxamide -   (6-11) 3,4-dichloro-N-(2-cyanophenyl)isothiazole-5-carboxamide -   (6-14) penthiopyrad -   (6-16)     N-[2-(1,3-dimethylbutyl)phenyl]-1-methyl-4-(trifluoromethyl)-1H-pyrrole-3-carboxamide

Very particular preference is given to active compound combinations E in which the carboxamide of the formula (V) (group 6) is selected from the list below:

-   (6-2) boscalid -   (6-6) fenhexamid -   (6-7) carpropamid -   (6-9) picobenzamid -   (6-14) penthiopyrad

Emphasis is given to the active compound combinations E listed in Table 5 below:

TABLE 5 Active compound combinations E Carboxamide of No. Carboxamide of the formula (I) the formula (V) E-1 (1-1) N-(3′,4′-dichloro-5-fluoro-1,1′-biphenyl-2-yl)-3- (6-2) boscalid (difluoromethyl)-1-methyl-1H-pyrazole-4-carboxamide E-2 (1-1) N-(3′,4′-dichloro-5-fluoro-1,1′-biphenyl-2-yl)-3- (6-6) fenhexamid (difluoromethyl)-1-methyl-1H-pyrazole-4-carboxamide E-3 (1-1) N-(3′,4′-dichloro-5-fluoro-1,1′-biphenyl-2-yl)-3- (6-7) carpropamid (difluoromethyl)-1-methyl-1H-pyrazole-4-carboxamide E-4 (1-1) N-(3′,4′-dichloro-5-fluoro-1,1′-biphenyl-2-yl)-3- (6-9) picobenzamid (difluoromethyl)-1-methyl-1H-pyrazole-4-carboxamide E-5 (1-1) N-(3′,4′-dichloro-5-fluoro-1,1′-biphenyl-2-yl)-3- (6-14) penthiopyrad (difluoromethyl)-1-methyl-1H-pyrazole-4-carboxamide E-6 (1-7) N-(4′-bromo-1,1′-biphenyl-2-yl)-4-(difluoromethyl)- (6-2) boscalid 2-methyl-1,3-thiazole-5-carboxamide E-7 (1-7) N-(4′-bromo-1,1′-biphenyl-2-yl)-4-(difluoromethyl)- (6-6) fenhexamid 2-methyl-1,3-thiazole-5-carboxamide E-8 (1-7) N-(4′-bromo-1,1′-biphenyl-2-yl)-4-(difluoromethyl)- (6-7) carpropamid 2-methyl-1,3-thiazole-5-carboxamide E-9 (1-7) N-(4′-bromo-1,1′-biphenyl-2-yl)-4-(difluoromethyl)- (6-9) picobenzamid 2-methyl-1,3-thiazole-5-carboxamide E-10 (1-7) N-(4′-bromo-1,1′-biphenyl-2-yl)-4-(difluoromethyl)- (6-14) penthiopyrad 2-methyl-1,3-thiazole-5-carboxamide E-11 (1-8) 4-(difluoromethyl)-2-methyl-N-[4′-(trifluoromethyl)- (6-2) boscalid 1,1′-biphenyl-2-yl]-1,3-thiazole-5-carboxamide E-12 (1-8) 4-(difluoromethyl)-2-methyl-N-[4′-(trifluoromethyl)- (6-6) fenhexamid 1,1′-biphenyl-2-yl]-1,3-thiazole-5-carboxamide E-13 (1-8) 4-(difluoromethyl)-2-methyl-N-[4′-(trifluoromethyl)- (6-7) carpropamid 1,1′-biphenyl-2-yl]-1,3-thiazole-5-carboxamide E-14 (1-8) 4-(difluoromethyl)-2-methyl-N-[4′-(trifluoromethyl)- (6-9) picobenzamid 1,1′-biphenyl-2-yl]-1,3-thiazole-5-carboxamide E-15 (1-8) 4-(difluoromethyl)-2-methyl-N-[4′-(trifluoromethyl)- (6-14) penthiopyrad 1,1′-biphenyl-2-yl]-1,3-thiazole-5-carboxamide E-16 (1-9) N-(4′-chloro-3′-fluoro-1,1′-biphenyl-2-yl)-4- (6-2) boscalid (difluoromethyl)-2-methyl-1,3-thiazole-5-carboxamide E-17 (1-9) N-(4′-chloro-3′-fluoro-1,1′-biphenyl-2-yl)-4- (6-6) fenhexamid (difluoromethyl)-2-methyl-1,3-thiazole-5-carboxamide E-18 (1-9) N-(4′-chloro-3′-fluoro-1,1′-biphenyl-2-yl)-4- (6-7) carpropamid (difluoromethyl)-2-methyl-1,3-thiazole-5-carboxamide E-19 (1-9) N-(4′-chloro-3′-fluoro-1,1′-biphenyl-2-yl)-4- (6-9) picobenzamid (difluoromethyl)-2-methyl-1,3-thiazole-5-carboxamide E-20 (1-9) N-(4′-chloro-3′-fluoro-1,1′-biphenyl-2-yl)-4- (6-14) penthiopyrad (difluoromethyl)-2-methyl-1,3-thiazole-5-carboxamide

In addition to a carboxamide of the formula (I) (group 1), the active compound combinations F also comprise a dithiocarbamate (group 7) selected from

-   (7-1) mancozeb -   (7-2) maneb -   (7-3) metiram -   (7-4) propineb -   (7-5) thiram -   (7-6) zineb -   (7-7) ziram

Preference is given to active compound combinations F in which the dithiocarbamate (group 7) is selected from the following list:

-   (7-1) mancozeb -   (7-2) maneb -   (7-4) propineb -   (7-5) thiram -   (7-6) zineb

Particular preference is given to active compound combinations F in which the dithiocarbamate (group 7) is selected from the following list:

-   (7-1) mancozeb -   (7-4) propineb

Emphasis is given to the active compound combinations F listed in Table 6 below:

TABLE 6 Active compound combinations F No. Carboxamide of the formula (I) Dithiocarbamate F-1 (1-1) N-(3′,4′-dichloro-5-fluoro-1,1′-biphenyl-2-yl)-3-(difluoromethyl)- (7-1) mancozeb 1-methyl-1H-pyrazole-4-carboxamide F-2 (1-1) N-(3′,4′-dichloro-5-fluoro-1,1′-biphenyl-2-yl)-3-(difluoromethyl)- (7-4) propineb 1-methyl-1H-pyrazole-4-carboxamide F-3 (1-7) N-(4′-bromo-1,1′-biphenyl-2-yl)-4-(difluoromethyl)-2-methyl-1,3- (7-1) mancozeb thiazole-5-carboxamide F-4 (1-7) N-(4′-bromo-1,1′-biphenyl-2-yl)-4-(difluoromethyl)-2-methyl-1,3- (7-4) propineb thiazole-5-carboxamide F-5 (1-8) 4-(difluoromethyl)-2-methyl-N-[4′-(trifluoromethyl)-1,1′- (7-1) mancozeb biphenyl-2-yl]-1,3-thiazole-5-carboxamide F-6 (1-8) 4-(difluoromethyl)-2-methyl-N-[4′-(trifluoromethyl)-1,1′ (7-4) propineb biphenyl-2-yl]-1,3-thiazole-5-carboxamide F-7 (1-9) N-(4′-chloro-3′-fluoro-1,1′-biphenyl-2-yl)-4-(difluoromethyl)-2- (7-1) mancozeb methyl-1,3-thiazole-5-carboxamide F-8 (1-9) N-(4′-chloro-3′-fluoro-1,1′-biphenyl-2-yl)-4-(difluoromethyl)-2- (7-4) propineb methyl-1,3-thiazole-5-carboxamide

In addition to a carboxamide of the formula (I) (group 1), the active compound combinations G also comprise an acylalanine of the formula (VI) (group 8)

in which * and R²⁶ are as defined above.

Preference is given to active compound combinations G in which the acylalanine of the formula (VI) (group 8) is selected from the following list:

-   (8-1) benalaxyl -   (8-2) furalaxyl -   (8-3) metalaxyl -   (8-4) metalaxyl-M -   (8-5) benalaxyl-M

Particular preference is given to active compound combinations G in which the acylalanine of the formula (VI) (group 8) is selected from the following list:

-   (8-3) metalaxyl -   (8-4) metalaxyl-M -   (8-5) benalaxyl-M

Emphasis is given to the active compound combinations G listed in Table 7 below:

TABLE 7 Active compound combinations G Acylalanine of No. Carboxamide of the formula (I) the formula (VI) G-1 (1-1) N-(3′,4′-dichloro-5-fluoro-1,1′- (8-3) metalaxyl biphenyl-2-yl)-3-(difluoromethyl)-1- methyl-1H-pyrazole-4-carboxamide G-2 (1-1) N-(3′,4′-dichloro-5-fluoro-1,1′- (8-4) metalaxyl-M biphenyl-2-yl)-3-(difluoromethyl)-1- methyl-1H-pyrazole-4-carboxamide G-3 (1-1) N-(3′,4′-dichloro-5-fluoro-1,1′- (8-5) benalaxyl-M biphenyl-2-yl)-3-(difluoromethyl)-1- methyl-1H-pyrazole-4-carboxamide G-4 (1-7) N-(4′-bromo-1,1′-biphenyl-2-yl)- (8-3) metalaxyl 4-(difluoromethyl)-2-methyl-1,3- thiazole-5-carboxamide G-5 (1-7) N-(4′-bromo-1,1′-biphenyl-2-yl)- (8-4) metalaxyl-M 4-(difluoromethyl)-2-methyl-1,3- thiazole-5-carboxamide G-6 (1-7) N-(4′-bromo-1,1′-biphenyl-2-yl)- (8-5) benalaxyl-M 4-(difluoromethyl)-2-methyl-1,3- thiazole-5-carboxamide G-7 (1-8) 4-(difluoromethyl)-2-methyl-N-[4′- (8-3) metalaxyl (trifluoromethyl)-1,1′-biphenyl-2-yl]- 1,3-thiazole-5-carboxamide G-8 (1-8) 4-(difluoromethyl)-2-methyl-N-[4′- (8-4) metalaxyl-M (trifluoromethyl)-1,1′-biphenyl-2-yl]- 1,3-thiazole-5-carboxamide G-9 (1-8) 4-(difluoromethyl)-2-methyl-N-[4′- (8-5) benalaxyl-M (trifluoromethyl)-1,1′-biphenyl-2-yl]- 1,3-thiazole-5-carboxamide G-10 (1-9) N-(4′-chloro-3′-fluoro-1,1′-biphenyl- (8-3) metalaxyl 2-yl)-4-(difluoromethyl)-2-methyl- 1,3-thiazole-5-carboxamide G-11 (1-9) N-(4′-chloro-3′-fluoro-1,1′-biphenyl- (8-4) metalaxyl-M 2-yl)-4-(difluoromethyl)-2-methyl- 1,3-thiazole-5-carboxamide G-12 (1-9) N-(4′-chloro-3′-fluoro-1,1′-biphenyl- (8-5) benalaxyl-M 2-yl)-4-(difluoromethyl)-2-methyl- 1,3-thiazole-5-carboxamide

In addition to a carboxamide of the formula (I) (group 1), the active compound combinations H also comprise an anilinopyrimidine (group 9) selected from

-   (9-1) cyprodinil -   (9-2) mepanipyrim -   (9-3) pyrimethanil

Emphasis is given to the active compound combinations H listed in Table 8 below:

TABLE 8 Active compound combinations H No. Carboxamide of the formula (I) Anilinopyrimidine H-1 (1-1) N-(3′,4′-dichloro-5-fluoro-1,1′- (9-1) cyprodinil biphenyl-2-yl)-3-(difluoromethyl)-1- methyl-1H-pyrazole-4-carboxamide H-2 (1-1) N-(3′,4′-dichloro-5-fluoro-1,1′- (9-2) mepanipyrim biphenyl-2-yl)-3-(difluoromethyl)-1- methyl-1H-pyrazole-4-carboxamide H-3 (1-1) N-(3′,4′-dichloro-5-fluoro-1,1′- (9-3) pyrimethanil biphenyl-2-yl)-3-(difluoromethyl)-1- methyl-1H-pyrazole-4-carboxamide H-4 (1-7) N-(4′-bromo-1,1′-biphenyl-2-yl)- (9-1) cyprodinil 4-(difluoromethyl)-2-methyl-1,3- thiazole-5-carboxamide H-5 (1-7) N-(4′-bromo-1,1′-biphenyl-2-yl)- (9-2) mepanipyrim 4-(difluoromethyl)-2-methyl-1,3- thiazole-5-carboxamide H-6 (1-7) N-(4′-bromo-1,1′-biphenyl-2-yl)- (9-3) pyrimethanil 4-(difluoromethyl)-2-methyl-1,3- thiazole-5-carboxamide H-7 (1-8) 4-(difluoromethyl)-2-methyl-N- (9-1) cyprodinil [4′-(trifluoromethyl)-1,1′-biphenyl-2-yl]- 1,3-thiazole-5-carboxamide H-8 (1-8) 4-(difluoromethyl)-2-methyl-N- (9-2) mepanipyrim [4′-(trifluoromethyl)-1,1′-biphenyl-2-yl]- 1,3-thiazole-5-carboxamide H-9 (1-8) 4-(difluoromethyl)-2-methyl-N- (9-3) pyrimethanil [4′-(trifluoromethyl)-1,1′-biphenyl-2-yl]- 1,3-thiazole-5-carboxamide H-10 (1-9) N-(4′-chloro-3′-fluoro-1,1′-biphenyl- (9-1) cyprodinil 2-yl)-4-(difluoromethyl)-2-methyl- 1,3-thiazole-5-carboxamide H-11 (1-9) N-(4′-chloro-3′-fluoro-1,1′-biphenyl- (9-2) mepanipyrim 2-yl)-4-(difluoromethyl)-2-methyl- 1,3-thiazole-5-carboxamide H-12 (1-9) N-(4′-chloro-3′-fluoro-1,1′-biphenyl- (9-3) pyrimethanil 2-yl)-4-(difluoromethyl)-2-methyl- 1,3-thiazole-5-carboxamide

In addition to a carboxamide of the formula (I) (group 1), the active compound combinations I also comprise a benzimidazole of the formula (VIII) (group 10)

in which R²⁸, R²⁹, R³⁰ and R³¹ are as defined above.

Preference is given to active compound combinations I in which the benzimidazole of the formula (VIII) (group 10) is selected form the following list:

-   (10-1)     6-chloro-5-[(3,5-dimethylisoxazol-4-yl)sulphonyl]-2,2-difluoro-5H-[1,3]dioxolo[4,5-f]-benzimidazole -   (10-2) benomyl -   (10-3) carbendazim -   (10-4) chlorfenazole -   (10-5) fuberidazole -   (10-6) thiabendazole

Particular preference is given to active compound combinations I in which the benzimidazole of the formula (VIII) (group 10) is:

-   (10-3) carbendazim

Emphasis is given to the active compound combinations I listed in Table 9 below:

TABLE 9 Active compound combinations I Benzimidazole of No. Carboxamide of the formula (I) the formula (VIII) I-1 (1-1) N-(3′,4′-dichloro-5-fluoro-1,1′- (10-3) carbendazim biphenyl-2-yl)-3-(difluoromethyl)-1- methyl-1H-pyrazole-4-carboxamide I-2 (1-7) N-(4′-bromo-1,1′-biphenyl-2-yl)- (10-3) carbendazim 4-(difluoromethyl)-2-methyl-1,3- thiazole-5-carboxamide I-3 (1-8) 4-(difluoromethyl)-2-methyl-N- (10-3) carbendazim [4′-(trifluoromethyl)-1,1′-biphenyl-2-yl]- 1,3-thiazole-5-carboxamide I-4 (1-9) N-(4′-chloro-3′-fluoro-1,1′- (10-3) carbendazim biphenyl-2-yl)-4-(difluoromethyl)-2- methyl-1,3-thiazole-5-carboxamide

In addition to a carboxamide of the formula (I) (group 1), the active compound combinations J also comprise a carbamate (group 11) of the formula (IX)

in which R³² and R³³ are as defined above.

Preference is given to active compound combinations J in which the carbamate (group 11) is selected from the following list:

-   (11-1) diethofencarb -   (11-2) propamocarb -   (11-3) propamocarb-hydrochloride -   (11-4) propamocarb-fosetyl

Emphasis is given to the active compound combinations J listed in Table 10 below:

TABLE 10 Active compound combinations J Carbamate No. Carboxamide of the formula (I) of the formula (IX) J-1 (1-1) N-(3′,4′-dichloro-5-fluoro-1,1′-biphenyl-2-yl)-3- (11-2) propamocarb (difluoromethyl)-1-methyl-1H-pyrazole-4-carboxamide J-2 (1-1) N-(3′,4′-dichloro-5-fluoro-1,1′-biphenyl-2-yl)-3- (11-3) propamocarb- (difluoromethyl)-1-methyl-1H-pyrazole-4-carboxamide hydrochloride J-3 (1-1) N-(3′,4′-dichloro-5-fluoro-1,1′-biphenyl-2-yl)-3- (11-4) propamocarb-fosetyl (difluoromethyl)-1-methyl-1H-pyrazole-4-carboxamide J-4 (1-7) N-(4′-bromo-1,1′-biphenyl-2-yl)-4-(difluoromethyl)- (11-2) propamocarb 2-methyl-1,3-thiazole-5-carboxamide J-5 (1-7) N-(4′-bromo-1,1′-biphenyl-2-yl)-4-(difluoromethyl)- (11-3) propamocarb- 2-methyl-1,3-thiazole-5-carboxamide hydrochloride J-6 (1-7) N-(4′-bromo-1,1′-biphenyl-2-yl)-4-(difluoromethyl)- (11-4) propamocarb-fosetyl 2-methyl-1,3-thiazole-5-carboxamide J-7 (1-8) 4-(difluoromethyl)-2-methyl-N-[4′-(trifluoromethyl)- (11-2) propamocarb 1,1′-biphenyl-2-yl]-1,3-thiazole-5-carboxamide J-8 (1-8) 4-(difluoromethyl)-2-methyl-N-[4′-(trifluoromethyl)- (11-3) propamocarb- 1,11-biphenyl-2-yl]-1,3-thiazole-5-carboxamide hydrochloride J-9 (1-8) 4-(difluoromethyl)-2-methyl-N-[4′-(trifluoromethyl)- (11-4) propamocarb-fosetyl 1,1′-biphenyl-2-yl]-1,3-thiazole-5-carboxamide J-10 (1-9) N-(4′-chloro-3′-fluoro-1,1′-biphenyl-2-yl)-4- (11-2) propamocarb (difluoromethyl)-2-methyl-1,3-thiazole-5-carboxamide J-11 (1-9) N-(4′-chloro-3′-fluoro-1,1′-biphenyl-2-yl)-4- (11-3) propamocarb- (difluoromethyl)-2-methyl-1,3-thiazole-5-carboxamide hydrochloride J-12 (1-9) N-(4′-chloro-3′-fluoro-1,1′-biphenyl-2-yl)-4- (11-4) propamocarb-fosetyl (difluoromethyl)-2-methyl-1,3-thiazole-5-carboxamide

In addition to a carboxamide of the formula (I) (group 1), the active compound combinations K also comprise a dicarboximide (group 12) selected from

-   (12-1) captafol -   (12-2) captan -   (12-3) folpet -   (12-4) iprodione -   (12-5) procymidone -   (12-6) vinclozolin

Preference is given to active compound combinations K in which the dicarboximide (group 12) is selected from the following list:

-   (12-2) captan -   (12-3) folpet -   (12-4) iprodione

Emphasis is given to the active compound combinations K listed in Table 11 below:

TABLE 11 Active compound combinations K No. Carboxamide of the formula (I) Dicarboximide K-1 (1-1) N-(3′,4′-dichloro-5-fluoro-1,1′-biphenyl-2-yl)-3-(difluoromethyl)- (12-2) captan 1-methyl-1H-pyrazole-4-carboxamide K-2 (1-1) N-(3′,4′-dichloro-5-fluoro-1,1′-biphenyl-2-yl)-3-(difluoromethyl)- (12-3) folpet 1-methyl-1H-pyrazole-4-carboxamide K-3 (1-1) N-(3′,4′-dichloro-5-fluoro-1,1′-biphenyl-2-yl)-3-(difluoromethyl)- (12-4) iprodione 1-methyl-1H-pyrazole-4-carboxamide K-4 (1-7) N-(4′-bromo-1,1′-biphenyl-2-yl)-4-(difluoromethyl)-2-methyl-1,3- (12-2) captan thiazole-5-carboxamide K-5 (1-7) N-(4′-bromo-1,1′-biphenyl-2-yl)-4-(difluoromethyl)-2-methyl-1,3- (12-3) folpet thiazole-5-carboxamide K-6 (1-7) N-(4′-bromo-1,1′-biphenyl-2-yl)-4-(difluoromethyl)-2-methyl-1,3- (12-4) iprodione thiazole-5-carboxamide K-7 (1-8) 4-(difluoromethyl)-2-methyl-N-[4′-(trifluoromethyl)-1,1′- (12-2) captan biphenyl-2-yl]-1,3-thiazole-5-carboxamide K-8 (1-8) 4-(difluoromethyl)-2-methyl-N-[4′-(trifluoromethyl)-1,1′- (12-3) folpet biphenyl-2-yl]-1,3-thiazole-5-carboxamide K-9 (1-8) 4-(difluoromethyl)-2-methyl-N-[4′-(trifluoromethyl)-1,1′- (12-4) iprodione biphenyl-2-y11-1,3-thiazole-5-carboxamide K-10 (1-9) N-(4′-chloro-3′-fluoro-1,1′-biphenyl-2-yl)-4-(difluoromethyl)-2- (12-2) captan methyl-1,3-thiazole-5-carboxamide K-11 (1-9) N-(4′-chloro-3′-fluoro-1,1′-biphenyl-2-yl)-4-(difluoromethyl)-2- (12-3) folpet methyl-1,3-thiazole-5-carboxamide K-12 (1-9) N-(4′-chloro-3′-fluoro-1,1′-biphenyl-2-yl)-4-(difluoromethyl)-2- (12-4) iprodione methyl-1,3-thiazole-5-carboxamide

In addition to a carboxamide of the formula (I) (group 1), the active compound combinations L also comprise a guanidine (group 13) selected from

-   (13-1) dodine -   (13-2) guazatine -   (13-3) iminoctadine triacetate -   (13-4) iminoctadine tris(albesilate)

Preference is given to active compound combinations L in which the guanidine (group 13) is selected from the following list:

-   (13-1) dodine -   (13-2) guazatine

Emphasis is given to the active compound combinations L listed in Table 12 below:

TABLE 12 Active compound combinations L No. Carboxamide of the formula (I) Guanidine L-1 (1-1) N-(3′,4′-dichloro-5-fluoro-1,1′-biphenyl-2-yl)-3-(difluoromethyl)- (13-1) dodine 1-methyl-1H-pyrazole-4-carboxamide L-2 (1-1) N-(3′,4′-dichloro-5-fluoro-1,1′-biphenyl-2-yl)-3-(difluoromethyl)- (13-2) guazatine 1-methyl-1H-pyrazole-4-carboxamide L-3 (1-7) N-(4′-bromo-1,1′-biphenyl-2-yl)-4-(difluoromethyl)-2-methyl-1,3- (13-1) dodine thiazole-5 -carboxamide L-4 (1-7) N-(4′-bromo-1,1′-biphenyl-2-yl)-4-(difluoromethyl)-2-methyl-1,3- (13-2) guazatine thiazole-5-carboxamide L-5 (1-8) 4-(difluoromethyl)-2-methyl-N-[4′-(trifluoromethyl)-1,1′- (13-1) dodine biphenyl-2-yl]-1,3-thiazole-5-carboxamide L-6 (1-8) 4-(difluoromethyl)-2-methyl-N-[4′-(trifluoromethyl)-1,1′- (13-2) guazatine biphenyl-2-yl]-1,3-thiazole-5-carboxamide L-7 (1-9) N-(4′-chloro-3′-fluoro-1,1′-biphenyl-2-yl)-4-(difluoromethyl)-2- (13-1) dodine methyl-1,3-thiazole-5-carboxamide L-8 (1-9) N-(4′-chloro-3′-fluoro-1,1′-biphenyl-2-yl)-4-(difluoromethyl)-2- methyl-1,3-thiazole-5-carboxamide (13-2) guazatine

In addition to a carboxamide of the formula (I) (group 1), the active compound combinations M also comprise an imidazole (group 14) selected from

-   (14-1) cyazofamid -   (14-2) prochloraz -   (14-3) triazoxide -   (14-4) pefurazoate

Preference is given to active compound combinations M in which the imidazole (group 14) is selected from the following list:

-   (14-2) prochloraz -   (14-3) triazoxide

Emphasis is given to the active compound combinations M listed in Table 13 below:

TABLE 13 Active compound combinations M No. Carboxamide of the formula (I) Imidazole M-1 (1-1) N-(3′,4′-dichloro-5-fluoro-1,1′-biphenyl-2-yl)-3-(difluoromethyl)- (14-2) prochloraz 1-methyl-1H-pyrazole-4-carboxamide M-2 (1-1) N-(3′,4′-dichloro-5-fluoro-1,1′-biphenyl-2-yl)-3-(difluoromethyl)- (14-3) triazoxide 1-methyl-1H-pyrazole-4-carboxamide M-3 (1-7) N-(4′-bromo-1,1′-biphenyl-2-yl)-4-(difluoromethyl)-2-methyl-1,3- (14-2) prochloraz thiazole-5 -carboxamide M-4 (1-7) N-(4′-bromo-1,1′-biphenyl-2-yl)-4-(difluoromethyl)-2-methyl-1,3- (14-3) triazoxide thiazole-5-carboxamide M-5 (1-8) 4-(difluoromethyl)-2-methyl-N-[4′-(trifluoromethyl)-1,1′- (14-2) prochloraz biphenyl-2-yl]-1,3-thiazole-5-carboxamide M-6 (1-8) 4-(difluoromethyl)-2-methyl-N-[4′-(trifluoromethyl)-1,1′- (14-3) triazoxide biphenyl-2-yl]-1,3-thiazole-5-carboxamide M-7 (1-9) N-(4′-chloro-3′-fluoro-1,1′-biphenyl-2-yl)-4-(difluoromethyl)-2- (14-2) prochloraz methyl-1,3-thiazole-5-carboxamide M-8 (1-9) N-(4′-chloro-3′-fluoro-1,1′-biphenyl-2-yl)-4-(difluoromethyl)-2- (14-3) triazoxide methyl-1,3-thiazole-5-carboxamide

In addition to a carboxamide of the formula (I) (group 1), the active compound combinations N also comprise a morpholine (group 15) of the formula (X)

in which R³⁴, R³⁵ and R³⁶ are as defined above.

Preference is given to active compound combinations N in which the morpholine (group 15) of the formula (X) is selected from the following list:

-   (15-1) aldimorph -   (15-2) tridemorph -   (15-3) dodemorph -   (15-4) fenpropimorph -   (15-5) dimethomorph

Particular preference is given to active compound combinations N in which the morpholine (group 15) of the formula (X) is selected from the following list:

-   (15-4) fenpropimorph -   (15-5) dimethomorph

Emphasis is given to the active compound combinations N listed in Table 14 below:

TABLE 14 Active compound combinations N Morpholine of No. Carboxamide of the formula (I) the formula (X) N-1 (1-1) N-(3′,4′-dichloro-5-fluoro-1,1′-biphenyl-2-yl)-3- (15-4) fenpropimorph (difluoromethyl)-1-methyl-1H-pyrazole-4-carboxamide N-2 (1-7) N-(4′-bromo-1,1′-biphenyl-2-yl)-4-(difluoromethyl)- (15-4) fenpropimorph 2-methyl-1,3-thiazole-5-carboxamide N-3 (1-8) 4-(difluoromethyl)-2-methyl-N-[4′-(trifluoromethyl)- (15-4) fenpropimorph 1,1′-biphenyl-2-yl]-1,3-thiazole-5-carboxamide N-4 (1-9) N-(4′-chloro-3′-fluoro-1,1′-biphenyl-2-yl)-4- (15-4) fenpropimorph (difluoromethyl)-2-methyl-1,3-thiazole-5-carboxamide

In addition to a carboxamide of the formula (I) (group 1), the active compound combinations 0 also comprise a pyrrole (group 16) of the formula (XI)

in which R³⁷, R³⁸ and R³⁹ are as defined above.

Preference is given to active compound combinations 0 in which the pyrrole (group 16) of the formula (XI) is selected from the following list:

-   (16-1) fenpiclonil -   (16-2) fludioxonil -   (16-3) pyrrolnitrin

Particular preference is given to active compound combinations 0 in which the pyrrole (group 16) of the formula (XI) is selected from the following list:

-   (16-2) fludioxonil

Emphasis is given to the active compound combinations 0 listed in Table 15 below:

TABLE 15 Active compound combinations O Pyrrole of No. Carboxamide of the formula (I) the formula (XI) O-1 (1-1) N-(3′,4′-dichloro-5-fluoro-1,1′- (16-2) fludioxonil biphenyl-2-yl)-3-(difluoromethyl)-1- methyl-1H-pyrazole-4-carboxamide O-2 (1-7) N-(4′-bromo-1,1′-biphenyl-2-yl)- (16-2) fludioxonil 4-(difluoromethyl)-2-methyl-1,3- thiazole-5-carboxamide O-3 (1-8) 4-(difluoromethyl)-2-methyl-N- (16-2) fludioxonil [4′-(trifluoromethyl)-1,1′-biphenyl-2-yl]- 1,3-thiazole-5-carboxamide O-4 (1-9) N-(4′-chloro-3′-fluoro-1,1′- (16-2) fludioxonil biphenyl-2-yl)-4-(difluoromethyl)-2- methyl-1,3-thiazole-5-carboxamide

In addition to a carboxamide of the formula (I) (group 1), the active compound combinations P also comprise a phosphonate (group 17) selected from

-   (17-1) fosetyl-Al -   (17-2) phosphonic acid

Emphasis is given to the active compound combinations P listed in Table 16 below:

TABLE 16 Active compound combinations P No. Carboxamide of the formula (I) Phosphonate P-1 (1-1) N-(3′,4′-dichloro-5-fluoro-1,1′- (17-1) fosetyl-Al biphenyl-2-yl)-3-(difluoromethyl)-1- methyl-1H-pyrazole-4-carboxamide P-2 (1-7) N-(4′-bromo-1,1′-biphenyl-2-yl)- (17-1) fosetyl-Al 4-(difluoromethyl)-2-methyl-1,3- thiazole-5-carboxamide P-3 (1-8) 4-(difluoromethyl)-2-methyl-N- (17-1) fosetyl-Al [4′-(trifluoromethyl)-1,1′-biphenyl-2-yl]- 1,3-thiazole-5-carboxamide P-4 (1-9) N-(4′-chloro-3′-fluoro-1,1′- (17-1) fosetyl-Al biphenyl-2-yl)-4-(difluoromethyl)-2- methyl-1,3-thiazole-5-carboxamide

In addition to a carboxamide of the formula (I) (group 1), the active compound combinations Q also comprise a fungicide (group 19) selected from

-   (19-1) acibenzolar-S-methyl -   (19-2) chlorothalonil -   (19-3) cymoxanil -   (19-4) edifenphos -   (19-5) famoxadone -   (19-6) fluazinam -   (19-7) copper oxychloride -   (19-8) copper hydroxide -   (19-9) oxadixyl -   (19-10) spiroxamine -   (19-11) dithianon -   (19-12) metrafenone -   (19-13) fenamidone -   (19-14) 2,3-dibutyl-6-chlorothieno[2,3-d]pyrimidin-4(3H)one -   (19-15) probenazole -   (19-16) isoprothiolane -   (19-17) kasugamycin -   (19-18) phthalide -   (19-19) ferimzone -   (19-20) tricyclazole -   (19-21)     N-({4-[(cyclopropylamino)carbonyl]phenyl}sulphonyl)-2-methoxybenzamide -   (19-22)     2-(4-chlorophenyl)-N-{2-[3-methoxy-4-(prop-2-yn-1-yloxy)phenyl]ethyl}-2-(prop-2-yn-1-yloxy)acetamide

Preference is given to active compound combinations Q in which the fungicide (group 19) is selected from the following list:

-   (19-1) acibenzolar-S-methyl -   (19-2) chlorothalonil -   (19-3) cymoxanil -   (19-5) famoxadone -   (19-6) fluazinam -   (19-7) copper oxychloride -   (19-9) oxadixyl -   (19-10) spiroxamine -   (19-13) fenamidone -   (19-21)     N-({4-[(cyclopropylamino)carbonyl]phenyl}sulphonyl)-2-methoxybenzamide -   (19-22)     2-(4-chlorophenyl)-N-{2-[3-methoxy-4-(prop-2-yn-1-yloxy)phenyl]ethyl}-2-(prop-2-yn-1-yloxy)acetamide

Particular preference is given to active compound combinations Q in which the fungicide (group 19) is selected from the following list:

-   (19-2) chlorothalonil -   (19-7) copper oxychloride -   (19-10) spiroxamine -   (19-21)     N-({4-[(cyclopropylamino)carbonyl]phenyl}sulphonyl)-2-methoxybenzamide -   (19-22)     2-(4-chlorophenyl)-N-{2-[3-methoxy-4-(prop-2-yn-1-yloxy)phenyl]ethyl}-2-(prop-2-yn-1-yloxy)acetamide

Emphasis is given to the active compound combinations Q listed in Table 17 below:

TABLE 17 Active compound combinations Q No. Carboxamide of the formula (I) Fungicide Q-1 (1-1) N-(3′,4′-dichloro-5-fluoro-1,1′-biphenyl-2-yl)-3- (19-2) chlorothalonil (difluoromethyl)-1-methyl-1H-pyrazole-4-carboxamide Q-2 (1-1) N-(3′,4′-dichloro-5-fluoro-1,1′-biphenyl-2-yl)-3- (19-7) copper oxychloride (difluoromethyl)-1-methyl-1H-pyrazole-4-carboxamide Q-3 (1-1) N-(3′,4′-dichloro-5-fluoro-1,1′-biphenyl-2-yl)-3- (19-10) spiroxamine (difluoromethyl)-1-methyl-1H-pyrazole-4-carboxamide Q-4 (1-1) N-(3′,4′-dichloro-5-fluoro-1,1′-biphenyl-2-yl)-3- (19-21) N-({4-[(cyclopropylamino)- (difluoromethyl)-1-methyl-1H-pyrazole-4-carboxamide carbonyl]phenyl}sulphonyl)-2- methoxybenzamide Q-5 (1-1) N-(3′,4′-dichloro-5-fluoro-1,1′-biphenyl-2-yl)-3- (19-22) 2-(4-chlorophenyl)-N-{2-[3- (difluoromethyl)-1-methyl-1H-pyrazole-4-carboxamide methoxy-4-(prop-2-yn-1-yloxy)phenyl]- ethyl}-2-(prop-2-yn-1-yloxy)acetamide Q-6 (1-7) N-(4′-bromo-1,1′-biphenyl-2-yl)-4-(difluoromethyl)- (19-2) chlorothalonil 2-methyl-1,3-thiazole-5-carboxamide Q-7 (1-7) N-(4′-bromo-1,1′-biphenyl-2-yl)-4-(difluoromethyl)- (19-7) copper oxychloride 2-methyl-1,3-thiazole-5-carboxamide Q-8 (1-7) N-(4′-bromo-1,1′-biphenyl-2-yl)-4-(difluoromethyl)- (19-10) spiroxamine 2-methyl-1,3-thiazole-5-carboxamide Q-9 (1-7) N-(4′-bromo-1,1′-biphenyl-2-yl)-4-(difluoromethyl)- (19-21) N-({4-[(cyclopropylamino)- 2-methyl-1,3-thiazole-5-carboxamide carbonyl]phenyl}sulphonyl)-2- Q-10 (1-7) N-(4′-bromo-1,1′-biphenyl-2-yl)-4-(difluoromethyl)- (19-22) 2-(4-chloropheny1)-N-{2-[3 2-methyl-1,3-thiazole-5-carboxamide methoxy-4-(prop-2-yn-1-yloxy)phenyl]- ethyl}-2-(prop-2-yn-1-yloxy)acetamide Q-11 (1-8) 4-(difluoromethyl)-2-methyl-N-[4′-(trifluoromethyl)- (19-2) chlorothalonil 1,1′-biphenyl-2-yl]-1,3-thiazole-5-carboxamide Q-12 (1-8) 4-(difluoromethyl)-2-methyl-N-[4′-(trifluoromethyl)- (19-7) copper oxychloride 1,1′-biphenyl-2-yl]-1,3-thiazole-5-carboxamide Q-13 (1-8) 4-(difluoromethyl)-2-methyl-N-[4′-(trifluoromethyl)- (19-10) spiroxamine 1,1′-biphenyl-2-yl]-1,3-thiazole-5-carboxamide Q-14 (1-8) 4-(difluoromethyl)-2-methyl-N-[4′-(trifluoromethyl)- (19-21) N-({4-(cyclopropylamino)- 1,1′-biphenyl-2-yl]-1,3-thiazole-5-carboxamide carbonyl]phenyl}sulphonyl)-2- methoxybenzamide Q-15 (1-8) 4-(difluoromethyl)-2-methyl-N-[4′-(trifluoromethyl)- (19-22) 2-(4-chlorophenyl)-N-{2-[3- 1,1′-biphenyl-2-yl]-1,3-thiazole-5-carboxamide methoxy-4-(prop-2-yn-1-yloxy)phenyl]- ethyl}-2-(prop-2-yn-1-yloxy)acetamide Q-16 (1-9) N-(4′-chloro-3′-fluoro-1,1′-biphenyl-2-yl)-4- (19-2) chlorothalonil (difluoromethyl)-2-methyl-1,3-thiazole-5-carboxamide Q-17 (1-9) N-(4′-chloro-3′-fluoro-1,1′-biphenyl-2-yl)-4- (19-7) copper oxychloride (difluoromethyl)-2-methyl-1,3-thiazole-5-carboxamide Q-18 (1-9) N-(4′-chloro-3′-fluoro-1,1′-biphenyl-2-yl)-4- (19-10) spiroxamine (difluoromethyl)-2-methyl-1,3-thiazole-5-carboxamide Q-19 (1-9) N-(4′-chloro-3′-fluoro-1,1′-biphenyl-2-yl)-4- (19-21) N-({4-[(cyclopropylamino)- (difluoromethyl)-2-methyl-1,3-thiazole-5-carboxamide carbonyl]phenyl}sulphonyl)-2- methoxybenzamide Q-20 (1-9) N-(4′-chloro-3′-fluoro-1,1′-biphenyl-2-yl)-4- (19-22) 2-(4-chlorophenyl)-N-{2-[3- (difluoromethyl)-2-methyl-1,3-thiazole-5-carboxamide methoxy-4-(prop-2-yn-1-yloxy)phenyl]- ethyl}-2-(prop-2-yn-1-yloxy)acetamide

In addition to a carboxamide of the formula (I) (group 1), the active compound combinations R also comprise a (thio)urea derivative (group 20) selected from

-   (20-1) pencycuron -   (20-2) thiophanate-methyl -   (20-3) thiophanate-ethyl

Preference is given to active compound combinations R in which the (thio)urea derivative (group 20) is selected from the following list:

-   (20-1) pencycuron -   (20-2) thiophanate-methyl

Emphasis is given to the active compound combinations R listed in Table 18 below:

TABLE 18 Active compound combinations R No. Carboxamide of the formula (I) (Thio)urea derivative R-1 (1-1) N-(3′,4′-dichloro-5-fluoro-1,1′- (20-1) pencycuron biphenyl-2-yl)-3-(difluoromethyl)-1- methyl-1H-pyrazole-4-carboxamide R-2 (1-7) N-(4′-bromo-1,1′-biphenyl-2-yl)- (20-1) pencycuron 4-(difluoromethyl)-2-methyl-1,3-thiazole- 5-carboxamide R-3 (1-8) 4-(difluoromethyl)-2-methyl-N-[4′- (20-1) pencycuron (trifluoromethyl)-1,1′-biphenyl-2-yl]- 1,3-thiazole-5-carboxamide R-4 (1-9) N-(4′-chloro-3′-fluoro-1,1′- (20-1) pencycuron biphenyl-2-yl)-4-(difluoromethyl)-2- methyl-1,3-thiazole-5-carboxamide

In addition to a carboxamide of the formula (I) (group 1), the active compound combinations S also comprise a triazolopyrimidine (group 22) of the formula (XIV)

in which R⁴³, R⁴⁴, R⁴⁵, R⁴⁶, R⁴⁷, R⁴⁸, R⁴⁹ and R⁵⁰ are as defined above.

Preference is given to active compound combinations S in which the triazolopyrimidine (group 22) of the formula (XIV) is selected from the list below:

-   (22-1)     5-chloro-N-[(1S)-2,2,2-trifluoro-1-methylethyl]-6-(2,4,6-trifluorophenyl)[1,2,4]triazolo-[1,5-a]pyrimidine-7-amine -   (22-2)     5-chloro-N-[(1R)-1,2-dimethylpropyl]-6-(2,4,6-trifluorophenyl)[1,2,4]triazolo[1,5-a]-pyrimidine-7-amine -   (22-3)     5-chloro-6-(2-chloro-6-fluorophenyl)-7-(4-methylpiperidin-1-yl)[1,2,4]triazolo[1,5-a]-pyrimidine -   (22-4)     5-chloro-6-(2,4,6-trifluorophenyl)-7-(4-methylpiperidin-1-yl)[1,2,4]triazolo[1,5-a]pyrimidine

Particular preference is given to active compound combinations S in which the triazolopyrimidine (group 22) of the formula (XIV) is selected from the list below:

-   (22-1)     5-chloro-N-[(1S)-2,2,2-trifluoro-1-methylethyl]-6-(2,4,6-trifluorophenyl)[1,2,4]triazolo-[1,5-a]pyrimidine-7-amine -   (22-2)     5-chloro-N—[(R)-1,2-dimethylpropyl]-6-(2,4,6-trifluorophenyl)[1,2,4]triazolo[1,5-a]-pyrimidine-7-amine -   (22-4)     5-chloro-6-(2,4,6-trifluorophenyl)-7-(4-methylpiperidin-1-yl)[1,2,4]triazolo[1,5-a]pyrimidine

Emphasis is given to the active compound combinations S listed in Table 19 below:

TABLE 19 Active compound combinations S No. Carboxamide of the formula (I) Triazolopyrimidine of the formula (XIV) S-1 (1-1) N-(3′,4′-dichloro-5-fluoro-1,1′- (22-1) 5-chloro-N-[(1S)-2,2,2-trifluoro-1- biphenyl-2-yl)-3-(difluoromethyl)-1- methylethyl]-6-(2,4,6-trifluorophenyl)- methyl-1H-pyrazole-4-carboxamide [1,2,4]triazolo[1,5-a]pyrimidine-7-amine S-2 (1-1) N-(3′,4′-dichloro-5-fluoro-1,1′- (22-2) 5-chloro-N-[(1R)-1,2-dimethylpropyl]-6- biphenyl-2-yl)-3-(difluoromethyl)-1- (2,4,6-trifluorophenyl)[1,2,4]triazolo[1,5-a]- methyl-1H-pyrazole-4-carboxamide pyrimidine-7-amine S-3 (1-1) N-(3′,4′-dichloro-5-fluoro-1,1′- (22-4) 5-chloro-6-(2,4,6-trifluorophenyl)-7-(4- biphenyl-2-yl)-3-(difluoromethyl)-1- methylpiperidin-1-yl)[1,2,4]triazolo[1,5-a]pyri- methyl-1H-pyrazole-4-carboxamide midine S-4 (1-7) N-(4′-bromo-1,1′-biphenyl-2-yl)-4- (22-1) 5-chloro-N-[(1S)-2,2,2-trifluoro-1- (difluoromethyl)-2-methyl-1,3-thiazole-5- methylethyl]-6-(2,4,6-trifluorophenyl)- carboxamide [1,2,4]triazolo[1,5-a]pyrimidine-7-amine S-5 (1-7) N-(4′-bromo-1,1′-biphenyl-2-yl)-4- (22-2) 5-chloro-N-[(1R)-1,2-dimethylpropyl]-6- (difluoromethyl)-2-methyl-1,3-thiazole-5- (2,4,6-trifluorophenyl)[1,2,4]triazolo[1,5-a]- carboxamide pyrimidine-7-amine S-6 (1-7) N-(4′-bromo-1,1′-biphenyl-2-yl)-4- (22-4) 5-chloro-6-(2,4,6-trifluorophenyl)-7-(4- (difluoromethyl)-2-methyl-1,3-thiazole-5- methylpiperidin-1-yl)[1,2,4]triazolo[1,5-a]pyri- carboxamide midine S-7 (1-8) 4-(difluoromethyl)-2-methyl-N[4′- (22-1) 5-chloro-N-[(1S)-2,2,2-trifluoro-1- (trifluoromethyl)-1,1′-biphenyl-2-yl]-1,3- methylethyl]-6-(2,4,6-trifluorophenyl)- thiazole-5-carboxamide [1,2,4]triazolo[1,5-a]pyrimidine-7-amine S-8 (1-8) 4-(difluoromethyl)-2-methyl-N[4′- (22-2) 5-chloro-N-[(1R)-1,2-dimethylpropyl]-6- (trifluoromethyl)-1,1′-biphenyl-2-yl]-1,3- (2,4,6-trifluorophenyl)[1,2,4]triazolo[1,5-a]- thiazole-5-carboxamide pyrimidine-7-amine S-9 (1-8) 4-(difluoromethyl)-2-methyl-N[4′- (22-4) 5-chloro-6-(2,4,6-trifluorophenyl)-7-(4- (trifluoromethyl)-1,1′-biphenyl-2-yl]-1,3- methylpiperidin-1-yl)[1,2,4]triazolo[1,5-a]pyri- thiazole-5-carboxamide midine S-10 (1-9) N-(4′-chloro-3′-fluoro-1,1′-biphenyl-2- (22-1) 5-chloro-N-[(1S)-2,2,2-trifluoro-1- yl)-4-(difluoromethyl)-2-methyl-1,3- methylethyl]-6-(2,4,6-trifluorophenyl)- thiazole-5-carboxamide [1,2,4]triazolo[1,5-a]pyrimidine-7-amine S-11 (1-9) N-(4′-chloro-3′-fluoro-1,1′-biphenyl-2- (22-2) 5-chloro-N-[(1R)-1,2-dimethylpropyl]-6- yl)-4-(difluoromethyl)-2-methyl-1,3- (2,4,6-trifluorophenyl)[1,2,4]triazolo[1,5-a]- thiazole-5-carboxamide pyrimidine-7-amine S-12 (1-9) N-(4′-chloro-3′-fluoro-1,1′-biphenyl-2- (22-4) 5-chloro-6-(2,4,6-trifluorophenyl)-7-(4- yl)-4-(difluoromethyl)-2-methyl-1,3- methylpiperidin-1-yl)[1,2,4]triazolo[1,5-a]pyri- thiazole-5-carboxamide midine

In addition to a carboxamide of the formula (I) (group 1), the active compound combinations T also comprise an iodochromone (group 23) of the formula (XV)

in which R⁵¹ and R⁵² are as defined above.

Preference is given to active compound combinations T in which the iodochromone (group 23) of the formula (XV) is selected from the following list:

-   (23-1) 2-butoxy-6-iodo-3-propylbenzopyran-4-one -   (23-2) 2-ethoxy-6-iodo-3-propylbenzopyran-4-one -   (23-3) 6-iodo-2-propoxy-3-propylbenzopyran-4-one -   (23-4) 2-but-2-ynyloxy-6-iodo-3-propylbenzopyran-4-one -   (23-5) 6-iodo-2-(1-methylbutoxy)-3-propylbenzopyran-4-one -   (23-6) 2-but-3-enyloxy-6-iodobenzopyran-4-one -   (23-7) 3-butyl-6-iodo-2-isopropoxybenzopyran-4-one

Particular preference is given to active compound combinations T in which the iodochromone (group 23) of the formula (XV) is selected from the following list:

-   (23-1) 2-butoxy-6-iodo-3-propylbenzopyran-4-one -   (23-2) 2-ethoxy-6-iodo-3-propylbenzopyran-4-one

Emphasis is given to the active compound combinations T listed in Table 20 below:

TABLE 20 Active compound combinations T Iodochromone of the No. Carboxamide of the formula (I) formula (XV) T-1 (1-1) N-(3′,4′-dichloro-5-fluoro-1,1′-biphenyl-2-yl)-3- (23-1) 2-butoxy-6-iodo-3- (difluoromethyl)-1-methyl-1H-pyrazole-4-carboxamide propylbenzopyran-4-one T-2 (1-1) N-(3′,4′-dichloro-5-fluoro-1,1′-biphenyl-2-yl)-3- (23-2) 2-ethoxy-6-iodo-3- (difluoromethyl)-1-methyl-1H-pyrazole-4-carboxamide propylbenzopyran-4-one T-3 (1-7) N-(4′-bromo-1,1′-biphenyl-2-yl)-4-(difluoromethyl)- (23-1) 2-butoxy-6-iodo-3- 2-methyl-1,3-thiazole-5-carboxamide propylbenzopyran-4-one T-4 (1-7) N-(4′-bromo-1,1′-biphenyl-2-yl)-4-(difluoromethyl)- (23-2) 2-ethoxy-6-iodo-3- 2-methyl-1,3-thiazole-5-carboxamide propylbenzopyran-4-one T-5 (1-8) 4-(difluoromethyl)-2-methyl-N[4′-(trifluoromethyl)-1,1′- (23-1) 2-butoxy-6-iodo-3- biphenyl-2-yl]-1,3-thiazole-5-carboxamide propylbenzopyran-4-one T-6 (1-8) 4-(difluoromethyl)-2-methyl-N-[4′-(trifluoromethyl)-1,1′- (23-2) 2-ethoxy-6-iodo-3- biphenyl-2-yl]-1,3-thiazole-5-carboxamide propylbenzopyran-4-one T-7 (1-9) N-(4′-chloro-3′-fluoro-1,1′-biphenyl-2-yl)-4-(difluoro- (23-1) 2-butoxy-6-iodo-3- methyl)-2-methyl-1,3-thiazole-5-carboxamide propylbenzopyran-4-one T-8 (1-9) N-(4′-chloro-3′-fluoro-1,1′-biphenyl-2-yl)-4-(difluoro- (23-2) 2-ethoxy-6-iodo-3- methyl)-2-methyl-1,3-thiazole-5-carboxamide propylbenzopyran-4-one

In addition to an active compound of the formula (I), the active compound combinations according to the invention comprise at least one active compound from the compounds of groups (2) to (23). In addition, they may also comprise further fungicidally active additives.

If the active compounds in the active compound combinations according to the invention are present in certain weight ratios, the synergistic effect is particularly pronounced. However, the weight ratios of the active compounds in the active compound combinations can be varied within a relatively wide range. In general, the combinations according to the invention comprise active compounds of the formula (I) and a mixing partner from one of the groups (2) to (23) in the mixing ratios listed in an exemplary manner in Table 21 below.

The mixing ratios are based on ratios by weight. The ratio is to be understood as active compound of the formula (I): mixing partner.

TABLE 21 Mixing ratios Particularly Preferred preferred Mixing partner mixing ratio mixing ratio Group (2): strobilurins 50:1 to 1:50 10:1 to 1:20 Group (3): triazoles except 50:1 to 1:50 20:1 to 1:20 for (3-15) (3-15): prothioconazole 50:1 to 1:50 10:1 to 1:20 Group (4): sulphenamides 1:1 to 1:150 1:1 to 1:100 Group (5): valinamides 50:1 to 1:50 10:1 to 1:20 Group (6): carboxamides 50:1 to 1:50 20:1 to 1:20 Group (7): dithiocarbamates 1:1 to 1:150 1:1 to 1:100 Group (8): acylalanines 10:1 to 1:150 5:1 to 1:100 Group (9): anilinopyrimidines 5:1 to 1:50 1:1 to 1:20 Group (10): benzimidazoles 10:1 to 1:50 5:1 to 1:20 Group (11): carbamates 1:1 to 1:150 1:1 to 1:100 except for (11-1) (11-1): diethofencarb 50:1 to 1:50 10:1 to 1:20 Group (12): (12-1)/(12-2)/(12-3) 1:1 to 1:150 1:5 to 1:100 Group (12): (12-4)/(12-5)/(12-6) 5:1 to 1:50 1:1 to 1:20 Group (13): guanidines 100:1 to 1:150 20:1 to 1:100 Group (14): imidazoles 50:1 to 1:50 10:1 to 1:20 Group (15): morpholines 50:1 to 1:50 10:1 to 1:20 Group (16): pyrroles 50:1 to 1:50 10:1 to 1:20 Group (17): phosphonates 10:1 to 1:150 1:1 to 1:100 Group (18): phenylethanamides 50:1 to 1:50 10:1 to 1:20 (19-1): acibenzolar-S-methyl 50:1 to 1:50 20:1 to 1:20 (19-2): chlorothalonil 1:1 to 1:150 1:1 to 1:100 (19-3): cymoxanil 10:1 to 1:50 5:1 to 1:20 (19-4): edifenphos 10:1 to 1:50 5:1 to 1:20 (19-5): famoxadone 50:1 to 1:50 10:1 to 1:20 (19-6): fluazinam 50:1 to 1:50 10:1 to 1:20 (19-7): copper oxychloride 1:1 to 1:150 1:5 to 1:100 (19-8): copper hydroxide 1:1 to 1:150 1:5 to 1:100 (19-9): oxadixyl 10:1 to 1:150 5:1 to 1:100 (19-10): spiroxamine 50:1 to 1:50 10:1 to 1:20 (19-11) dithianon 50:1 to 1:50 10:1 to 1:20 (19-12) metrafenone 50:1 to 1:50 10:1 to 1:20 (19-13) fenamidone 50:1 to 1:50 10:1 to 1:20 (19-14): 2,3-dibutyl-6-chlorothieno- 50:1 to 1:50 10:1 to 1:20 [2,3-d]pyrimidin-4(3H)one (19-15): probenazole 10:1 to 1:150 5:1 to 1:100 (19-16): isoprothiolane 10:1 to 1:150 5:1 to 1:100 (19-17): kasugamycin 50:1 to 1:50 10:1 to 1:20 (19-18): phthalide 10:1 to 1:150 5:1 to 1:100 (19-19): ferimzone 50:1 to 1:50 10:1 to 1:20 (19-20): tricyclazole 50:1 to 1:50 10:1 to 1:20 (19-21): N-({4-[(cyclopropylamino)- 10:1 to 1:150 5:1 to 1:100 carbonyl]phenyl}sulphonyl)-2- methoxybenzamide (19-22) 2-(4-chlorophenyl)-N-{2-[3- 50:1 to 1:50 10:1 to 1:20 methoxy-4-(prop-2-yn-1-yloxy)- phenyl]ethyl}-2-(prop-2-yn-1- yloxy)acetamide Group (20): (thio)urea derivatives 50:1 to 1:50 10:1 to 1:20 Group (21): amides 50:1 to 1:50 10:1 to 1:20 Group (22): triazolopyrimidines 50:1 to 1:50 10:1 to 1:20 Group (23): iodochromones 50:1 to 1:50 10:1 to 1:20

In each case, the mixing ratio is to be chosen such that a synergistic mixture is obtained. The mixing ratios between the compound of the formula (I) and a compound of one of the groups (2) to (23) may also vary between the individual compounds of a group.

The active compound combinations according to the invention have very good fungicidal properties and are suitable for controlling phytopathogenic fungi, such as Plasmodiophoromycetes, Oomycetes, Chytridiomycetes, Zygomycetes, Ascomycetes, Basidiomycetes, Deuteromycetes, etc.

The active compound combinations according to the invention are particularly suitable for controlling Erysiphe graminis, Pyrenophora teres and Leptosphaeria nodorum.

Some pathogens causing fungal diseases which come under the generic names listed above may be mentioned by way of example, but not by way of limitation:

Pythium species, such as, for example, Pythium ultimum; Phytophthora species, such as, for example, Phytophthora infestans; Pseudoperonospora species, such as, for example, Pseudoperonospora humuli or Pseudoperonospora cubensis; Plasmopara species, such as, for example, Plasmopara viticola; Bremia species, such as, for example, Bremia lactucae; Peronospora species, such as, for example, Peronospora pisi or P. brassicae; Erysiphe species, such as, for example, Erysiphe graminis; Sphaerotheca species, such as, for example, Sphaerotheca fuliginea; Podosphaera species, such as, for example, Podosphaera leucotricha; Venturia species, such as, for example, Venturia inaequalis; Pyrenophora species, such as, for example, Pyrenophora teres or P. graminea (conidia form: Drechslera, syn: Helminthosporium); Cochliobolus species, such as, for example, Cochliobolus sativus (conidia form: Drechslera, syn: Helminthosporium); Uromyces species, such as, for example, Uromyces appendiculatus; Puccinia species, such as, for example, Puccinia recondita; Sclerotinia species, such as, for example, Sclerotinia sclerotiorum; Tilletia species, such as, for example, Tilletia caries; Ustilago species, such as, for example, Ustilago nuda or Ustilago avenae; Pellicularia species, such as, for example, Pellicularia sasakii; Pyricularia species, such as, for example, Pyricularia oryzae; Fusarium species, such as, for example, Fusarium culmorum; Botrytis species, such as, for example, Botrytis cinerea; Septoria species, such as, for example, Septoria nodorum; Leptosphaeria species, such as, for example, Leptosphaeria nodorum; Cercospora species, such as, for example, Cercospora canescens; Alternaria species, such as, for example, Alternaria brassicae; Pseudocercosporella species, such as, for example, Pseudocercosporella herpotrichoides, Rhizoctonia species, such as, for example, Rhizoctonia solani.

The fact that the active compound combinations are well tolerated by plants at the concentrations required for controlling plant diseases permits a treatment of entire plants (above-ground parts of plants and roots), of propagation stock and seed, and of the soil. The active compound combinations according to the invention can be used for foliar application or else as seed dressings.

The active compound combinations according to the invention are also suitable for increasing the yield of crops. In addition, they show reduced toxicity and are well tolerated by plants.

According to the invention, it is possible to treat all plants and parts of plants. Plants are to be understood here as meaning all plants and plant populations, such as desired and undesired wild plants or crop plants (including naturally occurring crop plants). Crop plants can be plants which can be obtained by conventional breeding and optimization methods or by biotechnological and genetic engineering methods or combinations of these methods, including the transgenic plants and including plant cultivars which can or cannot be protected by plant breeders' certificates. Parts of plants are to be understood as meaning all above-ground and below-ground parts and organs of plants, such as shoot, leaf, flower and root, examples which may be mentioned being leaves, needles, stems, trunks, flowers, fruit bodies, fruits and seeds and also roots, tubers and rhizomes. Parts of plants also include harvested material and vegetative and generative propagation material, for example seedlings, tubers, rhizomes, cuttings and seeds.

The treatment of the plants and parts of plants according to the invention with the active compounds is carried out directly or by action on their environment, habitat or storage area according to customary treatment methods, for example by dipping, spraying, evaporating, atomizing, broadcasting, brushing-on and, in the case of propagation material, in particular in the case of seeds, furthermore by one- or multilayer coating.

As already mentioned above, it is possible to treat all plants and their parts according to the invention. In a preferred embodiment, wild plant species and plant cultivars, or those obtained by conventional biological breeding, such as crossing or protoplast fusion, and parts thereof, are treated. In a further preferred embodiment, transgenic plants and plant cultivars obtained by genetic engineering, if appropriate in combination with conventional methods (genetically modified organisms), and parts thereof, are treated. The term “parts” or “parts of plants” or “plant parts” has been explained above.

Particularly preferably, plants of the plant cultivars which are in each case commercially available or in use are treated according to the invention.

Depending on the plant species or plant cultivars, their location and growth conditions (soils, climate, vegetation period, diet), the treatment according to the invention may also result in superadditive (“synergistic”) effects. Thus, for example, reduced application rates and/or a widening of the activity spectrum and/or an increase in the activity of the substances and compositions which can be used according to the invention, better plant growth, increased tolerance to high or low temperatures, increased tolerance to drought or to water or soil salt content, increased flowering performance, easier harvesting, accelerated maturation, higher harvest yields, better quality and/or a higher nutritional value of the harvested products, better storage stability and/or processability of the harvested products are possible which exceed the effects which were actually to be expected.

The transgenic plants or plant cultivars (i.e. those obtained by genetic engineering) which are preferably to be treated according to the invention include all plants which, in the genetic modification, received genetic material which imparted particularly advantageous useful properties (“traits”) to these plants. Examples of such properties are better plant growth, increased tolerance to high or low temperatures, increased tolerance to drought or to water or soil salt content, increased flowering performance, easier harvesting, accelerated maturation, higher harvest yields, better quality and/or a higher nutritional value of the harvested products, better storage stability and/or processability of the harvested products. Further and particularly emphasized examples of such properties are a better defense of the plants against animal and microbial pests, such as against insects, mites, phytopathogenic fungi, bacteria and/or viruses, and also increased tolerance of the plants to certain herbicidally active compounds. Examples of transgenic plants which may be mentioned are the important crop plants, such as cereals (wheat, rice), maize, soya beans, potatoes, cotton, oilseed rape and also fruit plants (with the fruits apples, pears, citrus fruits and grapes), and particular emphasis is given to maize, soya beans, potatoes, cotton and oilseed rape. Traits that are emphasized in particular are increased defense of the plants against insects, by toxins formed in the plants, in particular those formed in the plants by the genetic material from Bacillus thuringiensis (for example by the genes CryIA(a), CryIA(b), CryIA(c), CryIIA, CryIIIA, CryIIIB2, Cry9c, Cry2Ab, Cry3Bb and CryIF and also combinations thereof) (hereinbelow referred to as “Bt plants”). Traits that are furthermore particularly emphasized are the increased tolerance of the plants to certain herbicidally active compounds, for example imidazolinones, sulphonylureas, glyphosates or phosphinotricin (for example the “PAT” gene). The genes which impart the desired traits in question can also be present in combinations with one another in the transgenic plants. Examples of “Bt plants” which may be mentioned are maize varieties, cotton varieties, soya bean varieties and potato varieties which are sold under the trade names YIELD GARD® (for example maize, cotton, soya bean), KnockOut® (for example maize), StarLink® (for example maize), Bollgard® (cotton), Nucoton® (cotton) and NewLeaf® (potato). Examples of herbicide-tolerant plants which may be mentioned are maize varieties, cotton varieties and soya bean varieties which are sold under the trade names Roundup Ready® (tolerance to glyphosates, for example maize, cotton, soya bean), Liberty Link® (tolerance to phosphinotricin, for example oilseed rape), IMI® (tolerance to imidazolinones) and STS® (tolerance to sulphonylureas, for example maize). Herbicide-resistant plants (plants bred in a conventional manner for herbicide tolerance) which may be mentioned also include the varieties sold under the name Clearfield® (for example maize). Of course, these statements also apply to plant cultivars which have these genetic traits or genetic traits still to be developed, and which will be developed and/or marketed in the future.

Depending on their particular physical and/or chemical properties, the active compound combinations according to the invention can be converted into the customary formulations, such as solutions, emulsions, suspensions, powders, dusts, foams, pastes, soluble powders, granules, aerosols, suspoemulsion concentrates, natural and synthetic substances impregnated with active compound and microencapsulations in polymeric substances and in coating compositions for seeds, and ULV cool and warm fogging formulations.

These formulations are produced in a known manner, for example by mixing the active compounds or active compound combinations with extenders, that is liquid solvents, liquefied gases under pressure, and/or solid carriers, optionally with the use of surfactants, that is emulsifiers and/or dispersants, and/or foam formers.

If the extender used is water, it is also possible to employ, for example, organic solvents as auxiliary solvents. Essentially, suitable liquid solvents are: aromatics such as xylene, toluene or alkylnaphthalenes, chlorinated aromatics or chlorinated aliphatic hydrocarbons such as chlorobenzenes, chloro-ethylenes or methylene chloride, aliphatic hydrocarbons such as cyclohexane or paraffins, for example petroleum fractions, mineral and vegetable oils, alcohols such as butanol or glycol and their ethers and esters, ketones such as acetone, methyl ethyl ketone, methyl isobutyl ketone or cyclohexanone, strongly polar solvents such as dimethylformamide and dimethyl sulphoxide, or else water.

Liquefied gaseous extenders or carriers are to be understood as meaning liquids which are gaseous at standard temperature and under atmospheric pressure, for example aerosol propellants such as butane, propane, nitrogen and carbon dioxide.

Suitable solid carriers are: for example ammonium salts, ground natural minerals such as kaolins, clays, talc, chalk, quartz, attapulgite, montmorillonite or diatomaceous earth, and ground synthetic minerals such as finely divided silica, alumina and silicates. Suitable solid carriers for granules are: for example crushed and fractionated natural rocks such as calcite, marble, pumice, sepiolite and dolomite, or else synthetic granules of inorganic and organic meals, and granules of organic material such as sawdust, coconut shells, maize cobs and tobacco stalks. Suitable emulsifiers and/or foam formers are: for example nonionic and anionic emulsifiers, such as polyoxyethylene fatty acid esters, polyoxyethylene fatty alcohol ethers, for example alkylaryl polyglycol ethers, alkylsulphonates, alkyl sulphates, arylsulphonates, or else protein hydrolysates. Suitable dispersants are: for example lignosulphite waste liquors and methylcellulose.

Tackifiers such as carboxymethylcellulose, natural and synthetic polymers in the form of powders, granules or latices, such as gum arabic, polyvinyl alcohol and polyvinyl acetate, or else natural phospholipids such as cephalins and lecithins and synthetic phospholipids can be used in the formulations. Other possible additives are mineral and vegetable oils.

It is possible to use colorants such as inorganic pigments, for example iron oxide, titanium oxide and Prussian Blue, and organic dyestuffs such as alizarin dyestuffs, azo dyestuffs and metal phthalocyanine dyestuffs, and trace nutrients such as salts of iron, manganese, boron, copper, cobalt, molybdenum and zinc.

The active compound content of the use forms prepared from the commercial formulations may be varied within wide ranges. The concentration of active compound of the use forms for controlling animal pests, such as insects and acarids, may be from 0.0000001 to 95% by weight of active compound and is preferably from 0.0001 to 1% by weight. Application is in a customary manner adapted to the use forms.

The formulations for controlling unwanted phytopathogenic fungi generally comprise between 0.1 and 95% by weight of active compounds, preferably between 0.5 and 90%.

The active compound combinations according to the invention can be used as such, in the form of their formulations or as the use forms prepared therefrom, such as ready-to-use solutions, emulsifiable concentrates, emulsions, suspensions, wettable powders, soluble powders, dusts and granules. They are used in a customary manner, for example by watering (drenching), drip irrigation, spraying, atomizing, broadcasting, dusting, foaming, spreading-on, and as a powder for dry seed treatment, a solution for seed treatment, a water-soluble powder for seed treatment, a water-soluble powder for slurry treatment, or by encrusting.

The active compound combinations according to the invention can, in commercial formulations and in the use forms prepared from these formulations, be present as a mixture with other active compounds, such as insecticides, attractants, sterilants, bactericides, acaricides, nematicides, fungicides, growth regulators or herbicides.

When using the active compound combinations according to the invention, the application rates can be varied within a relatively wide range, depending on the kind of application. In the treatment of parts of plants, the application rates of active compound combinations are generally between 0.1 and 10 000 g/ha, preferably between 10 and 1000 g/ha. In the treatment of seeds, the application rates of active compound combination are generally between 0.001 and 50 g per kilogram of seed, preferably between 0.01 and 10 g per kilogram of seed. In the treatment of the soil, the application rates of active compound combination are generally between 0.1 and 10 000 g/ha, preferably between 1 and 5000 g/ha.

The active compound combinations can be used as such, in the form of concentrates or in the form of generally customary formulations, such as powders, granules, solutions, suspensions, emulsions or pastes.

The formulations mentioned can be prepared in a manner known per se, for example by mixing the active compounds with at least one solvent or diluent, emulsifier, dispersant and/or binder or fixative, water repellent, if desired desiccants and UV stabilizers, and, if desired, colorants and pigments and other processing auxiliaries.

The good fungicidal action of the active compound combinations according to the invention is demonstrated by the examples below. While the individual active compounds show weaknesses in their fungicidal action, the combinations show an action which exceeds a simple sum of actions.

A synergistic effect in fungicides is always present when the fungicidal action of the active compound combinations exceeds the total of the action of the active compounds when applied individually.

The expected fungicidal action for a given combination of two active compounds can be calculated as follows, according to S. R. Colby (“Calculating Synergistic and Antagonistic Responses of Herbicide Combinations”, Weeds 1967, 15, 20-22):

If

-   X is the efficacy when employing active compound A at an application     rate of m g/ha, -   Y is the efficacy when employing active compound B at an application     rate of n g/ha and -   E is the efficacy when employing active compounds A and B at     application rates of m and n g/ha,     then

$E = {X + Y - \frac{X \times Y}{100}}$

Here, the efficacy is determined in %. 0% means an efficacy which corresponds to that of the control, whereas an efficacy of 100% means that no infection is observed.

If the actual fungicidal action exceeds the calculated value, the action of the combination is superadditive, i.e. a synergistic effect is present. In this case, the actually observed efficacy must exceed the value calculated using the above formula for the expected efficacy (E).

The invention is illustrated by the examples below. However, the invention is not limited to the examples.

USE EXAMPLES

In the use examples shown below, in each case mixtures of the carboxamides of the general formula (I) (group 1) below with the mixing partners given in each case (structural formulae see above) were tested.

Carboxamides of the formula (I) used:

Example A

Pyrenophora teres Test (Barley)/Curative

-   Solvent: 50 parts by weight of N,N-dimethylacetamide -   Emulsifier: 1 part by weight of alkylaryl polyglycol ether

To produce a suitable preparation of active compound, 1 part by weight of active compound or active compound combination is mixed with the stated amounts of solvent and emulsifier, and the concentrate is diluted with water to the desired concentration.

To test for curative activity, young plants are sprayed with a conidia suspension of Pyrenophora teres. The plants remain in an incubation cabinet at 20° C. and 100% relative atmospheric humidity for 48 hours. The plants are then sprayed with the preparation of active compound at the stated application rate.

The plants are placed in a greenhouse at a temperature of about 20° C. and a relative atmospheric humidity of about 80%.

Evaluation is carried out 12 days after the inoculation. 0% means an efficacy which corresponds to that of the control, whereas an efficacy of 100% means that no infection is observed.

The table below clearly shows that the activity found for the active compound combination according to the invention is higher than the calculated activity, i.e. that a synergistic effect is present.

TABLE A Pyrenophora teres test (barley)/curative Application rate of active compound Efficacy in % Active compounds in g/ha found* calc.** (1-1) 25 43 (2-2) fluoxastrobin 25 0 (3-17) tebuconazole 25 29 (1-1) + (2-2) fluoxastrobin (1:1) 25 + 25 71 43 (1-1) + (3-17) tebuconazole (1:1) 25 + 25 71 60 *found = activity found **calc. = activity calculated using Colby's formula

Example B

Erysiphe Test (Barley)/Protective

-   Solvent: 50 parts by weight of N,N-dimethylacetamide -   Emulsifier: 1 part by weight of alkylaryl polyglycol ether

To produce a suitable preparation of active compound, 1 part by weight of active compound or active compound combination is mixed with the stated amounts of solvent and emulsifier, and the concentrate is diluted with water to the desired concentration.

To test for protective activity, young plants are sprayed with the preparation of active compound at the stated application rate. After the spray coating has dried on, the plants are dusted with spores of Erysiphe graminis f.sp. hordei.

Plants are placed in a greenhouse at a temperature of about 20° C. and a relative atmospheric humidity of about 80% to promote the development of mildew pustules.

Evaluation is carried out 6 days after the inoculation. 0% means an efficacy which corresponds to that of the control, whereas an efficacy of 100% means that no infection is observed.

The table below clearly shows that the activity found for the active compound combination according to the invention is higher than the calculated activity, i.e. that a synergistic effect is present.

TABLE B Erysiphe test (barley)/protective Application rate of active compound Efficacy in % Active compounds in g/ha found* calc.** (1-1) 12.5 0 (2-4) trifloxystrobin 12.5 78 (3-15) prothioconazole 12.5 67 (1-1) + (2-4) trifloxystrobin (1:1) 12.5 + 12.5 94 78 (1-1) + (3-15) prothioconazole (1:1) 12.5 + 12.5 89 67 *found = activity found **calc. = activity calculated using Colby's formula

Example C

Puccinia Test (Wheat)/Curative

-   Solvent: 50 parts by weight of N,N-dimethylacetamide -   Emulsifier: 1 part by weight of alkylaryl polyglycol ether

To produce a suitable preparation of active compound, 1 part by weight of active compound is mixed with the stated amounts of solvent and emulsifier, and the concentrate is diluted with water to the desired concentration.

To test for curative activity, young plants are sprayed with a conidia suspension of Puccinia recondita. The plants remain in an incubation cabinet at 20° C. and 100% relative atmospheric humidity for 48 hours.

The plants are then sprayed with the preparation of active compound at the stated application rate.

The plants are placed in a greenhouse at a temperature of about 20° C. and a relative atmospheric humidity of about 80% to promote the development of rust pustules.

Evaluation is carried out 8 days after the inoculation. 0% means an efficacy which corresponds to that of the control, whereas an efficacy of 100% means that no infection is observed.

The table below clearly shows that the activity found for the active compound combination according to the invention is higher than the calculated activity, i.e. that a synergistic effect is present.

TABLE C Puccinia test (wheat)/curative Application rate of active compound Efficacy in % Active compounds in g/ha found* calc.** (1-1) 62.5 22 (19-10) spiroxamine 62.5 0 (6-14) 62.5 44 (6-11) 62.5 0 (2-11) picoxystrobin 62.5 78 (1-1) + (19-10) spiroxamine (1:1) 62.5 + 62.5 100 22 (1-1) + (6-14) (1:1) 62.5 + 62.5 67 57 (1-1) + (6-11) (1:1) 62.5 + 62.5 44 22 (1-1) + (2-11) picoxystrobin (1:1) 62.5 + 62.5 89 83 *found = activity found **calc. = activity calculated using Colby's formula

Example D

Gibberella zeae Test (Barley)/Curative

-   Solvent: 50 parts by weight of N,N-dimethylacetamide -   Emulsifier: 1 part by weight of alkylaryl polyglycol ether

To produce a suitable preparation of active compound, 1 part by weight of active compound is mixed with the stated amounts of solvent and emulsifier, and the concentrate is diluted with water to the desired concentration.

To test for curative activity, young plants are sprayed with a conidia suspension of Gibberella zeae. The plants remain in an incubation cabinet at 22° C. and 100% relative atmospheric humidity for 24 hours. The plants are then sprayed with the preparation of active compound at the stated application rate. After the spray coating has dried on, the plants remain in a greenhouse under translucent incubation hoods at a temperature of about 22° C. and a relative atmospheric humidity of about 100%.

Evaluation is carried out 6 days after the inoculation. 0% means an efficacy which corresponds to that of the control, whereas an efficacy of 100% means that no infection is observed.

The table below shows clearly that the activity found for the active compound combination according to the invention is higher than the calculated activity, i.e. that a synergistic effect is present.

TABLE D Gibberella zeae test (barley)/curative Application rate of active compound Efficacy in % Active compounds in g/ha found* calc.** (1-1) 62.5 40 (2-12) pyraclostrobin 62.5 80 (3-12) epoxyconazole 62.5 0 (1-1) + (2-12) pyraclostrobin (1:1) 62.5 + 62.5 90 88 (1-1) + (3-12) epoxyconazole (1:1) 62.5 + 62.5 60 40 *found = activity found **calc. = activity calculated using Colby's formula

Example E

Sphaerotheca fuliginea Test (Cucumber)/Protective

-   Solvents: 24.5 parts by weight of acetone     -   24.5 parts by weight of dimethylacetamide -   Emulsifier: 1 part by weight of alkylaryl polyglycol ether

To produce a suitable preparation of active compound, 1 part by weight of active compound is mixed with the stated amounts of solvents and emulsifier, and the concentrate is diluted with water to the desired concentration.

To test for protective activity, young plants are sprayed with the preparation of active compound at the stated application rate. After the spray coating has dried on, the plants are inoculated with an aqueous spore suspension of Sphaerotheca fuliginea.

The plants are then placed in a greenhouse at about 23° C. and a relative atmospheric humidity of about 70%.

Evaluation is carried out 7 days after the inoculation. 0% means an efficacy which corresponds to that of the control, whereas an efficacy of 100% means that no infection is observed.

The table below clearly shows that the activity found for the active compound combination according to the invention is higher than the calculated activity, i.e. that a synergistic effect is present.

TABLE E Sphaerotheca fuliginea test (cucumber)/protective Application rate of active compound Efficacy in % Active compounds in g/ha found* calc.** (1-1)  4 30  2 36  1 16  0.5 0 (1-7)  2 0  1 0  0.5 0 (2-1) azoxystrobin  0.5 20 (2-2) fluoxastrobin  1 0 (2-4) trifloxystrobin  2 10 (2-12) pyraclostrobin  2 0 (3-15) prothioconazole  1 43 (3-17) tebuconazole  1 10 (3-21) bitertanol  1 0 (4-2) tolylfluanid 20 0 (6-6) fenhexamid 20 0 (6-14) penthiopyrad  4 0 (7-1) mancozeb 20 0 (7-4) propineb 20 11 (9-3) pyrimethanil 20 0 (12-4) iprodione 20 0 (19-2) chlorothalonil 20 0 (19-10) spiroxamine 20 0 (22-1)  2 11 (22-2)  1 22 (1-1) + (2-1) azoxystrobin (1:1) 0.5 + 0.5 87 20 (1-7) + (2-1) azoxystrobin (1:1) 0.5 + 0.5 63 20 (1-1) + (2-2) fluoxastrobin (1:1)   1 + 1 95 16 (1-7) + (2-2) fluoxastrobin (1:1)   1 + 1 92 0 (1-1) + (2-4) trifloxystrobin (1:1)   2 + 2 57 42 (1-7) + (2-4) trifloxystrobin (1:1)   2 + 2 93 10 (1-1) + (2-12) pyraclostrobin (1:1)   2 + 2 53 36 (1-1) + (3-15) prothioconazole (1:1)   1 + 1 70 52 (1-1) + (3-17) tebuconazole (1:1)   1 + 1 90 24 (1-1) + (3-21) bitertanol (1:1)   1 + 1 50 16 (1-1) + (4-2) tolylfluanid (1:10)   2 + 20 98 36 (1-1) + (6-6) fenhexamid (1:10)   2 + 20 85 36 (1-1) + (6-14) penthiopyrad (1:1)   4 + 4 82 30 (1-1) + (7-1) mancozeb (1:10)   2 + 20 93 36 (1-1) + (7-4) propineb (1:10)   2 + 20 65 43 (1-1) + (9-3) pyrimethanil (1:10)   2 + 20 96 36 (1-1) + (12-4) iprodione (1:10)   2 + 20 74 36 (1-1) + (19-2) chlorothalonil (1:10)   2 + 20 91 36 (1-1) + (19-10) spiroxamine (1:10)   2 + 20 100 36 (1-1) + (22-1) (1:1)   2 + 2 67 43 (1-1) + (22-2) (1:1)   1 + 1 94 34 *found = activity found **calc. = activity calculated using Colby's formula

Example F

Alternaria solani Test (Tomato)/Protective

-   Solvents: 24.5 parts by weight of acetone     -   24.5 parts by weight of dimethylacetamide -   Emulsifier: 1 part by weight of alkylaryl polyglycol ether

To produce a suitable preparation of active compound, 1 part by weight of active compound is mixed with the stated amounts of solvents and emulsifier, and the concentrate is diluted with water to the desired concentration.

To test for protective activity, young plants are sprayed with the preparation of active compound at the stated application rate. After the spray coating has dried on, the plants are inoculated with an aqueous spore suspension of Alternaria solani.

The plants are then placed in an incubation cabinet at about 20° C. and 100% relative atmospheric humidity.

Evaluation is carried out 3 days after the inoculation. 0% means an efficacy which corresponds to that of the control, whereas an efficacy of 100% means that no infection is observed.

The table below clearly shows that the activity found for the active compound combination according to the invention is higher than the calculated activity, i.e. that a synergistic effect is present.

TABLE F Alternaria solani test (tomato)/protective Application rate of active compound Efficacy in % Active compounds in g/ha found* calc.** (1-1) 1 61 0.5 42 (1-7) 1 63 0.5 28 (2-3) 0.5 22 (3-3) propiconazole 0.5 3 (5-3) benthiavalicarb 1 5 (8-4) metalaxyl-M 0.5 7 (8-5) benalaxyl-M 0.5 14 (1-7) + (2-3) (1:1) 0.5 + 0.5 67 44 (1-7) + (3-3) propiconazole (1:1) 0.5 + 0.5 56 30 (1-1) + (5-3) benthiavalicarb (1:1)   1 + 1   77 63 (1-1) + (8-4) metalaxyl-M (1:1) 0.5 + 0.5 62 46 (1-1) + (8-5) benalaxyl-M (1:1) 0.5 + 0.5 67 50 *found = activity found **calc. = activity calculated using Colby's formula

Example G

Phytophthora infestans Test (Tomato)/Protective

-   Solvents: 24.5 parts by weight of acetone     -   24.5 parts by weight of dimethylacetamide -   Emulsifier: 1 part by weight of alkylaryl polyglycol ether

To produce a suitable preparation of active compound, 1 part by weight of active compound is mixed with the stated amounts of solvents and emulsifier, and the concentrate is diluted with water to the desired concentration.

To test for protective activity, young plants are sprayed with the preparation of active compound at the stated application rate. After the spray coating has dried on, the plants are inoculated with an aqueous spore suspension of Phytophthora infestans. The plants are then placed in an incubation cabinet at about 20° C. and 100% relative atmospheric humidity.

Evaluation is carried out 3 days after the inoculation. 0% means an efficacy which corresponds to that of the control, whereas an efficacy of 100% means that no infection is observed.

The table below clearly shows that the activity found for the active compound combination according to the invention is higher than the calculated activity, i.e. that a synergistic effect is present.

TABLE G Phytophthora infestans test (tomato)/protective Application rate of active compound Efficacy in % Active compounds in g/ha found* calc.** (1-1) 10 0 5 0 1 0 0.5 0 (4-2) tolylfluanid 10 0 (5-1) iprovalicarb 10 64 5 61 (5-3) benthiavalicarb 0.5 56 (19-13) fenamidone 0.5 41 (1-1) + (4-2) tolylfluanid (1:10)   1 + 10  51 0 (1-1) + (5-1) iprovalicarb (1:1)  10 + 10  88 64   5 + 5   77 61 (1-1) + (5-3) benthiavalicarb (1:1) 0.5 + 0.5 73 56 (1-1) + (19-13) fenamidone (1:1) 0.5 + 0.5 51 41 *found = activity found **calc. = activity calculated using Colby's formula

Example H

Botrytis cinerea Test (Bean)/Protective

-   Solvents: 24.5 parts by weight of acetone     -   24.5 parts by weight of dimethylacetamide -   Emulsifier: 1 part by weight of alkylaryl polyglycol ether

To produce a suitable preparation of active compound, 1 part by weight of active compound is mixed with the stated amounts of solvents and emulsifier, and the concentrate is diluted with water to the desired concentration.

To test for protective activity, young plants are sprayed with the preparation of active compound at the stated application rate. After the spray coating has dried on, 2 small pieces of agar colonized by Botrytis cinerea are placed onto each leaf. The inoculated plants are placed in a darkened chamber at about 20° C. and 100% relative atmospheric humidity.

The size of the infected areas on the leaves is evaluated 2 days after the inoculation. 0% means an efficacy which corresponds to that of the control, whereas an efficacy of 100% means that no infection is observed.

The table below clearly shows that the activity found for the active compound combination according to the invention is higher than the calculated activity, i.e. that a synergistic effect is present.

TABLE H Botrytis cinerea test (bean)/protective Application rate of active compound Efficacy in % Active compounds in g/ha found* calc.** (1-1) 5 54 (9-3) pyrimethanil 5 4 (12-4) iprodione 5 13 (1-1) + (9-3) pyrimethanil (1:1) 5 + 5 92 56 (1-1) + (12-4) iprodione (1:1) 5 + 5 100 60 *found = activity found **calc. = activity calculated using Colby's formula

Example I

Alternaria mali Test (In Vitro)/Microtitre Plates

The microtest is carried out in microtitre plates using potato dextrose broth (PDB) as liquid test medium. The active compounds are used as technical grade a.i., dissolved in acetone.

For inoculation, a spore suspension of Alternaria mali is used. After 5 days of incubation in the dark and with shaking (10 Hz), for each filled cavity of the microtitre plates, the light transmittance is determined with the aid of a spectrophotometer.

0% means an efficacy which corresponds to the growth in the controls, whereas an efficacy of 100% means that no fungal growth is observed.

The table below clearly shows that the activity found for the active compound combination according to the invention is higher than the calculated activity, i.e. that a synergistic effect is present.

TABLE I Alternaria mali test (in vitro)/microtitre plates Application rate of active compound Efficacy in % Active compounds in ppm found* calc.** (1-1) 0.03 51 0.003 25 (10-3) carbendazim 0.03 15 (19-3) fenamidone 0.003 2 (20-1) pencycuron 0.003 11 (1-1) + (10-3) carbendazim (1:1)  0.03 + 0.03  79 59 (1-1) + (19-3) fenamidone (1:1) 0.003 + 0.003 35 27 (1-1) + (20-1) pencycuron (1:1) 0.003 + 0.003 67 33 *found = activity found **calc. = activity calculated using Colby's formula

Example J

Rhizoctonia solani Test (In Vitro)/Microtitre Plates

The microtest is carried out in microtitre plates using potato dextrose broth (PDB) as liquid test medium. The active compounds are used as technical grade a.i., dissolved in acetone.

For inoculation, a mycelium suspension of Rhizoctonia solani is used. After 5 days of incubation in the dark and with shaking (10 Hz), for each filled cavity of the microtitre plates, the light transmittance is determined with the aid of a spectrophotometer.

0% means an efficacy which corresponds to the growth in the controls, whereas an efficacy of 100% means that no fungal growth is observed.

The table below clearly shows that the activity found for the active compound combination according to the invention is higher than the calculated activity, i.e. that a synergistic effect is present.

TABLE J Rhizoctonia solani test (in vitro)/microtitre plates Application rate of active compound Efficacy in % Active compounds in ppm found* calc.** (1-1) 0.3 80 0.1 40 (17-1) fosetyl-A1 0.3 24 (11-2) propamocarb 0.1 25 (1-1) + (17-1) fosetyl-A1 (1:1) 0.3 + 0.3 98 85 (1-1) + (11-2) propamocarb (1:1) 0.1 + 0.1 88 55 *found = activity found **calc. = activity calculated using Colby's formula

Example K

Septoria tritici Test (In Vitro)/Microtitre Plates

The microtest is carried out in microtitre plates using potato dextrose broth (PDB) as liquid test medium. The active compounds are used as technical grade a.i., dissolved in acetone.

For inoculation, a spore suspension of Septoria tritici is used. After 7 days of incubation in the dark and with shaking (10 Hz), for each filled cavity of the microtitre plates, the light transmittance is determined with the aid of a spectrophotometer.

0% means an efficacy which corresponds to the growth in the controls, whereas an efficacy of 100% means that no fungal growth is observed.

The table below clearly shows that the activity found for the active compound combination according to the invention is higher than the calculated activity, i.e. that a synergistic effect is present.

TABLE K Septoria tritici test (in vitro)/microtitre plates Application rate of active compound Efficacy in % Active compounds in ppm found* calc.** (1-1) 0.01 15 (14-3) triazoxide 0.01 29 (1-1) + (14-3) triazoxide (1:1) 0.01 + 0.01 69 40 *found = activity found **calc. = activity calculated using Colby's formula

Example L

Sphaerotheca fuliginea Test (Gherkin)/Protective

To produce a suitable preparation of active compound, the substance to be tested is homogenized in a mixture of acetone/Tween/water. The suspension is then diluted with water to the desired concentration.

Gherkin plants (Vert petit de Paris cultivar) are sown in starter cups on 50/50 peat soil/pozzolana soil substrate and cultivated at 20° C./23° C. At the 2-leaf stage, the plants are sprayed with the preparation of active compound at the stated application rate.

To test for protective activity, the plants are, after 24 h, sprayed with an aqueous spore suspension of Sphaerotheca fuliginea (100 000 spores/ml). The plants then remain at 20° C./25° C. and 60/70% relative atmospheric humidity.

Evaluation is carried out 21 days after the inoculation. 0% means an efficacy which corresponds to that of the control, whereas an efficacy of 100% means that no infection is observed.

The table below shows clearly that the activity found for the active compound combination according to the invention is higher than the calculated activity, i.e. that a synergistic effect is present.

TABLE L Sphaerotheca fuliginea test (gherkin)/protective Application rate of active compound Efficacy in % Active compounds in ppm found* calc.** (1-1) 8 60 (6-2) boscalid 8 50 (1-1) + (6-2) boscalid (1:1) 8 + 8 98 80 *found = activity found **calc. = activity calculated using Colby's formula 

The invention claimed is:
 1. A composition comprising (1-1) N-(3′,4′-dichloro-5-fluoro-1,1′-biphenyl-2-yl)-3-(difluoromethyl)-1-methyl-1H-pyrazole-4-carboxamide and at least one fungicidal compound selected from the group consisting of: (19-2) chlorothalonil; (19-10) spiroxamine; and (19-13) fenamidone wherein the weight ratio of (1-1) to (19-2), (19-10) or (19-13) is from 1:1 to 1:20, and wherein if the fungicidal compound is spiroxamine, then spiroxamine and N-(3′,4′-dichloro-5-fluoro-1,1′-biphenyl-2-yl)-3-(difluoromethyl)-1-methyl-1H-pyrazole-4-carboxamide are the only fungicidal compounds in the composition.
 2. A method for controlling unwanted phytopathogenic fungi, comprising applying a composition according to claim 1 to the unwanted phytopathogenic fungi, their habitat, or a combination thereof.
 3. A process for preparing a fungicidal composition, comprising mixing a composition according to claim 1 with an extender, a surfactant, or a combination thereof.
 4. The composition of claim 1 wherein the active compound is spiroxamine.
 5. The composition of claim 1, which comprises (1-1) N-(3′,4′-dichloro-5-fluoro-1,1′-biphenyl-2-yl)-3-(difluoromethyl)-1-methyl-1H-pyrazole-4-carboxamide and (19-2) chlorothalonil.
 6. The composition of claim 1, which comprises (1-1) N-(3′,4′-dichloro-5-fluoro-1,1′-biphenyl-2-yl)-3-(difluoromethyl)-1-methyl-1H-pyrazole-4-carboxamide and (19-13) fenamidone. 